CA2557743A1 - Modular stimulation lead network - Google Patents
Modular stimulation lead network Download PDFInfo
- Publication number
- CA2557743A1 CA2557743A1 CA002557743A CA2557743A CA2557743A1 CA 2557743 A1 CA2557743 A1 CA 2557743A1 CA 002557743 A CA002557743 A CA 002557743A CA 2557743 A CA2557743 A CA 2557743A CA 2557743 A1 CA2557743 A1 CA 2557743A1
- Authority
- CA
- Canada
- Prior art keywords
- stimulation
- elongated body
- kit
- coupling mechanism
- lead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000638 stimulation Effects 0.000 title claims abstract description 397
- 230000007246 mechanism Effects 0.000 claims abstract description 56
- 230000008878 coupling Effects 0.000 claims abstract description 51
- 238000010168 coupling process Methods 0.000 claims abstract description 51
- 238000005859 coupling reaction Methods 0.000 claims abstract description 51
- 230000000295 complement effect Effects 0.000 claims abstract description 20
- 230000008859 change Effects 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 abstract description 13
- 208000000094 Chronic Pain Diseases 0.000 abstract description 6
- 238000000034 method Methods 0.000 description 12
- 210000000278 spinal cord Anatomy 0.000 description 10
- 239000004020 conductor Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- WABPQHHGFIMREM-OIOBTWANSA-N lead-204 Chemical compound [204Pb] WABPQHHGFIMREM-OIOBTWANSA-N 0.000 description 7
- 238000002513 implantation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000009434 installation Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 3
- 241001269524 Dura Species 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007737 ion beam deposition Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
Abstract
A medical kit for treating an ailment, such as chronic pain, includes first and second medical leads, e.g., stimulation leads. Each lead comprises an elongated body and at least one operative element. The first medical lead comprises a coupling mechanism, such as a slot, and the second medical lead comprises a complementary mechanism, such as a rail, that slidably engages the coupling mechanism of the first medical lead.
Description
MODULAR STIMULATION LEAD NETWORK
FIELD OF THE INVENTION
The invention relates to the implantation of electrode leads within a patient's spine to treat disorders, such as chronic pain.
BACKGROUND OF THE INVENTION
It is known to treat chronic pain by electrically stimulating the spinal cord, spinal nerve roots, and other nerve bundles. In a typical procedure, one or more stimulation leads are introduced through the patient's back into the epidural space IO under fluoroscopy. Currently, there are two types of commercially available stimulation leads: a percutaneous lead and a surgical lead. A percutaneous lead comprises a cylindrical body with ring electrodes, and can be introduced into contact with the affected spinal tissue through a Touhy-like needle, which passes through the skin, between the desired vertebrae, and into the spinal cavity above the dura layer. For unilateral pain, a percutaneous lead is placed on the corresponding lateral side of the spinal cord. For bilateral pain, a percutaneous lead is placed down the midline of the spinal cord, or two percutaneous leads are placed down the respective sides of the midline. A surgical lead has a paddle on which multiple electrodes are arranged in independent columns, and is introduced into contact with the affected spinal tissue using a surgical procedure, and specifically, a laminectomy, which involves removal of the laminar vertebral tissue to allow both access to the dura layer and positioning of the lead.
After the stimulation leads) (whether percutaneous or surgical) are placed at the target area of the spinal cord, the leads) are anchored in place, and the proximal ends of the lead(s), or alternatively lead extensions, are passed through a tunnel leading to a subcutaneous pocket (typically made in the patient's abdominal area) where a neurostimulator is implanted. The leads) are connected to the neurostimulator, which is then operated to test the effect of stimulation and adjust the parameters of the stimulation for optimal pain relief. During this procedure, the patient provides verbal feedback regarding the presence of paresthesia over the pain area. Based on this feedback, the lead positions) may be adjusted and re-anchored if necessary.
Although surgical leads have been functionally superior to percutaneous leads, there is one major drawback-surgical leads require painful surgery performed by a neurosurgeon, whereas percutaneous leads can be introduced into the epidural space minimally invasively by an anesthesiologist using local anesthesia.
SUMMARY OF THE INVENTION
In one embodiment of the invention, a stimulation kit comprising first and second tissue stimulation leads is provided. The first stimulation lead comprises a first elongated body, a first stimulation element (e.g., an electrode), and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body. The second stimulation lead comprises a second elongated body, a second stimulation element (e.g., an electrode), and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism, e.g., in a rail and slot arrangement. The stimulation kit may optionally comprise a stimulation source configured to be coupled to the first and second stimulation leads.
Optionally, each of the stimulation leads comprises a plurality of stimulation elements in order to provide a more extensive stimulation coverage.
FIELD OF THE INVENTION
The invention relates to the implantation of electrode leads within a patient's spine to treat disorders, such as chronic pain.
BACKGROUND OF THE INVENTION
It is known to treat chronic pain by electrically stimulating the spinal cord, spinal nerve roots, and other nerve bundles. In a typical procedure, one or more stimulation leads are introduced through the patient's back into the epidural space IO under fluoroscopy. Currently, there are two types of commercially available stimulation leads: a percutaneous lead and a surgical lead. A percutaneous lead comprises a cylindrical body with ring electrodes, and can be introduced into contact with the affected spinal tissue through a Touhy-like needle, which passes through the skin, between the desired vertebrae, and into the spinal cavity above the dura layer. For unilateral pain, a percutaneous lead is placed on the corresponding lateral side of the spinal cord. For bilateral pain, a percutaneous lead is placed down the midline of the spinal cord, or two percutaneous leads are placed down the respective sides of the midline. A surgical lead has a paddle on which multiple electrodes are arranged in independent columns, and is introduced into contact with the affected spinal tissue using a surgical procedure, and specifically, a laminectomy, which involves removal of the laminar vertebral tissue to allow both access to the dura layer and positioning of the lead.
After the stimulation leads) (whether percutaneous or surgical) are placed at the target area of the spinal cord, the leads) are anchored in place, and the proximal ends of the lead(s), or alternatively lead extensions, are passed through a tunnel leading to a subcutaneous pocket (typically made in the patient's abdominal area) where a neurostimulator is implanted. The leads) are connected to the neurostimulator, which is then operated to test the effect of stimulation and adjust the parameters of the stimulation for optimal pain relief. During this procedure, the patient provides verbal feedback regarding the presence of paresthesia over the pain area. Based on this feedback, the lead positions) may be adjusted and re-anchored if necessary.
Although surgical leads have been functionally superior to percutaneous leads, there is one major drawback-surgical leads require painful surgery performed by a neurosurgeon, whereas percutaneous leads can be introduced into the epidural space minimally invasively by an anesthesiologist using local anesthesia.
SUMMARY OF THE INVENTION
In one embodiment of the invention, a stimulation kit comprising first and second tissue stimulation leads is provided. The first stimulation lead comprises a first elongated body, a first stimulation element (e.g., an electrode), and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body. The second stimulation lead comprises a second elongated body, a second stimulation element (e.g., an electrode), and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism, e.g., in a rail and slot arrangement. The stimulation kit may optionally comprise a stimulation source configured to be coupled to the first and second stimulation leads.
Optionally, each of the stimulation leads comprises a plurality of stimulation elements in order to provide a more extensive stimulation coverage.
The first and second elongated bodies may be cylindrically-shaped, although other shapes are possible depending on the particular application. The size of the elongated bodies can be any size that is consistent with the stimulation procedure in which the stimulation leads will be employed. Although, for medical procedures, such as spinal cord stimulation, the greatest cross-sectional dimension of at least one of the elongated bodies is preferably 5 mm or less in order to minimize the size of the opening through which the stimulation leads will be introduced. The elongated bodies can have the same length, or alternatively, one elongated body can be shorter than the other, such that, e.g., the shorter elongated body can be entirely delivered within the patient's body without any portion extending from the access opening. In one embodiment, the stimulation elements of the respective stimulation leads face the same direction, e.g., to focus the stimulation energy in one direction.
The stimulation elements may be mounted directly on the elongated bodies, or alternatively, may be mounted to some other element of the stimulation leads. For example, the second stimulation lead may have a flap on which the respective stimulation element is disposed. In this case, the flap may extend along a portion of the complementary coupling mechanism, so that it can be secured by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably engages the coupling mechanism of the first stimulation lead and released by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism of the first stimulation lead.
The distal end of the second elongated body may be configured to be in close contact with the first elongated body when engaging each other. Alternatively, the first elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementation coupling mechanism from the coupling mechanism of the first stimulation lead. In this case, the distal end of the second elongated body can be pre-curved to provide it with a predefined configuration. Optionally, the second elongated body may be configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body. For example, the kit may comprise a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry. Or the secondary stimulation lead may comprise a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
The kit may have more than two stimulation leads. For example, the first stimulation lead may comprise another coupling mechanism longitudinally extending along at least a portion of the respective elongated body, in which case, the kit may further comprise a third stimulation lead comprising an elongated body, a stimulation element mounted on the elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism of the first stimulation lead.
In one embodiment, the stimulation kit is similar to the previously described stimulation kit, with the exception that it comprises a guide and a stimulation lead.
The guide is similar to the first stimulation lead of the previously described stimulation kit, with the exception that it need not have a stimulation element.
In another embodiment, a medical kit is similar to the previously described stimulation kit, with the exception that the medical kit comprises first and second medical leads with respective operative elements that are not limited to stimulation elements, but rather can be any elements that are capable of performing a medical function within a targeted tissue region. In still another embodiment, the medical kit comprises a guide and a medical lead. The guide is similar to the first medical lead of the previously described medical kit, with the exception that it need not have an operative element.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings illustrate the design and utility of embodiments) of the invention, in which similar elements are referred to by common reference numerals, and in which:
Fig. 1 is a plan view of a modular stimulation lead kit arranged in accordance with one embodiment of the invention;
Fig. 2 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 1;
Fig. 3 is a cutaway perspective view of a primary stimulation lead used in the kit of Fig. 1;
Fig. 4 is a cutaway perspective view of a secondary stimulation lead used in the kit of Fig. 1;
Fig. 5 is a cross-sectional view of the stimulation lead assembly of Fig. 2, taken along the line 5-5;
Fig. 6 is a cutaway view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1;
Fig. 7 is a cross-sectional view of the stimulation lead assembly of Fig. 6, taken along the line 7-7;
Figs. 8A-8D are various views illustrating the installation of the kit of Fig.
1 into a patient's spine;
The stimulation elements may be mounted directly on the elongated bodies, or alternatively, may be mounted to some other element of the stimulation leads. For example, the second stimulation lead may have a flap on which the respective stimulation element is disposed. In this case, the flap may extend along a portion of the complementary coupling mechanism, so that it can be secured by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably engages the coupling mechanism of the first stimulation lead and released by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism of the first stimulation lead.
The distal end of the second elongated body may be configured to be in close contact with the first elongated body when engaging each other. Alternatively, the first elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementation coupling mechanism from the coupling mechanism of the first stimulation lead. In this case, the distal end of the second elongated body can be pre-curved to provide it with a predefined configuration. Optionally, the second elongated body may be configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body. For example, the kit may comprise a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry. Or the secondary stimulation lead may comprise a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
The kit may have more than two stimulation leads. For example, the first stimulation lead may comprise another coupling mechanism longitudinally extending along at least a portion of the respective elongated body, in which case, the kit may further comprise a third stimulation lead comprising an elongated body, a stimulation element mounted on the elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism of the first stimulation lead.
In one embodiment, the stimulation kit is similar to the previously described stimulation kit, with the exception that it comprises a guide and a stimulation lead.
The guide is similar to the first stimulation lead of the previously described stimulation kit, with the exception that it need not have a stimulation element.
In another embodiment, a medical kit is similar to the previously described stimulation kit, with the exception that the medical kit comprises first and second medical leads with respective operative elements that are not limited to stimulation elements, but rather can be any elements that are capable of performing a medical function within a targeted tissue region. In still another embodiment, the medical kit comprises a guide and a medical lead. The guide is similar to the first medical lead of the previously described medical kit, with the exception that it need not have an operative element.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings illustrate the design and utility of embodiments) of the invention, in which similar elements are referred to by common reference numerals, and in which:
Fig. 1 is a plan view of a modular stimulation lead kit arranged in accordance with one embodiment of the invention;
Fig. 2 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 1;
Fig. 3 is a cutaway perspective view of a primary stimulation lead used in the kit of Fig. 1;
Fig. 4 is a cutaway perspective view of a secondary stimulation lead used in the kit of Fig. 1;
Fig. 5 is a cross-sectional view of the stimulation lead assembly of Fig. 2, taken along the line 5-5;
Fig. 6 is a cutaway view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1;
Fig. 7 is a cross-sectional view of the stimulation lead assembly of Fig. 6, taken along the line 7-7;
Figs. 8A-8D are various views illustrating the installation of the kit of Fig.
1 into a patient's spine;
Fig. 9 is a plan view of another modular stimulation lead kit arranged in accordance with another embodiment of the invention;
Fig. 10 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 9;
Fig. 11 is a cross-sectional view of the secondary stimulation lead of Fig.
10, taken along the line 11-11;
Figs. 12A-12B are various views illustrating the installation of the kit of Fig. 9 into a patient's spine;
Fig. 13 is a partially cutaway top view of the distal end of an alternative primary stimulation lead that can be used in kit of Fig. 1;
Fig. 14a is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig.
13 is used, wherein the secondary stimulation leads are shown in a normally curved geometry that converges towards the primary stimulation lead;
Fig. 15a is a cross-sectional view of the stimulation lead assembly of Fig.
14a, taken along the line 15a-15a;
Fig. 14b is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig.
13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a stylet is introduced;
Fig. 15b is a cross-sectional view of the stimulation lead assembly of Fig.
14b, taken along the line 15b-15b;
Fig. 14c is a cutaway top view of another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a pullwire is tensioned;
Fig. 15c is a cross-sectional view of the stimulation lead assembly of Fig.
14c, taken along the line 15c-15c;
Fig. 14d is a cutaway top view of still another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 3 is used, wherein the secondary stimulation leads can be placed into a curved geometry that bows away from the primary stimulation lead;
Fig. 15d is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15d-15d;
Fig. 15e is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15e-15e;
Fig. 15f is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15f-15f;
Fig. 16 is a cutaway top view of an alternative stimulation lead assembly;
Fig. 17 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing an electrode flap of a secondary stimulation lead constrained by the primary stimulation lead; and Fig. 18 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing the electrode flap of the secondary stimulation lead released by the primary stimulation lead.
DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS
Referring now to Fig. 1, a modular stimulation lead kit 100 arranged in accordance with one embodiment of the invention, generally comprises a primary stimulation lead 102 and two secondary stimulation leads 104, which are configured to be percutaneously delivered and implanted into the epidural space of a patient's spine, an implantable electrical stimulation source 106 configured for delivering stimulation energy to the stimulation leads 102/104, and an optional extension lead 105 configured for connecting the stimulation leads 102/104 to the remotely implanted stimulation source 106. As will be described in further detail below, the secondary stimulation leads 104 can be attached to the primary stimulation lead 102 to form a modularized stimulation lead assembly 110, as illustrated in Fig. 2.
It should be noted that although the kit 100 illustrated in Fig. 1 is described herein as being used in spinal cord stimulation (SCS) for the treatment of chronic pain, the kit 100, or a modification of the kit 100, can be used in an SCS
procedure to treat other ailments, or can used in other applications other than SCS
procedures, such as peripheral nervous system stimulation, sacral root stimulation, and brain tissue stimulation, including cortical and deep brain stimulation. In the latter case, the stimulation leads 102/104 can be delivered through a miniature cranial burr hole into the brain tissue.
The primary stimulation lead 102 comprises an elongated sheath body 112 having a proximal end 114 and a distal end 116. The sheath body 112 is composed of a suitably flexible material (such as polyurethane, silicone, etc.), which may either be resilient or non-resilient, and may be formed via an extrusion process or by any other suitable means. The distal end 116 of the sheath body 112 is soft and tapered to prevent injury to nerve roots that exit the spinal cord when delivered into the epidural space of the patient's spine. In the illustrated embodiment, the sheath body 112 is cylindrically-shaped and sized to fit through a Touhy-like needle (not shown).
In this case, the diameter of the sheath body 112 is preferably less than 5 mm to allow it to be percutaneously introduced through a needle. More preferably, the diameter of the sheath body 112 is within the range of 1 mm to 3 mm, so that the primary stimulation lead 102, along with the secondary stimulation leads 104 described below, can comfortably fit within the epidural space of the patient.
The sheath body 112 may have other cross-sectional geometries, such as elliptical, rectangular, triangular, etc. If rectangular, the width of the primary stimulation lead 102 can be up to 5 mm, since the width of an epidural space is greater than its height. The sheath body 112 may have an optional lumen (not shown) for receiving a stylet (not shown) that axially stiffens the sheath body 112 to facilitate percutaneous introduction of the primary stimulation lead 102 within the epidural space of the patient's spine, as will be described in further detail below.
The primary stimulation lead 102 further comprises a plurality of terminals (in this case, three) mounted on the proximal end 114 of the sheath body 112, and a plurality of stimulation elements, and in particular electrodes 120 (in this case, three), mounted on the distal end 116 of the sheath body 112. The terminals 118 are formed of ring-shaped elements composed of a suitable biocompatible metallic material, such as platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials, and can be mounted to the sheath body 112 in an interference fit arrangement.
In the illustrated embodiment, the electrodes 120 are formed on one circumferential side of the sheath body 112 (shown best in Fig. 3) in order to focus stimulation energy in one direction, thereby maximizing energy efficiency. The electrodes 120 can be formed onto the sheath body 112 using known deposition processes, such as sputtering, vapor deposition, ion beam deposition, electroplating over a deposited seed layer, or a combination of these processes.
Alternatively, the electrodes 120 can be formed onto the sheath body 112 as a thin sheet or foil of electrically conductive metal affixed to the wall of the sheath body 112. The electrodes 120 can be composed of the same electrically conductive and biocompatible material as the terminals 118, e.g., platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials.
The primary stimulation lead 102 further comprises a plurality of conductors 122 (shown in Fig. 3) extending through the sheath body 112 and connecting each electrode 120 with a respective terminal 118. The conductors 122 are composed of a suitably electrically conductive material that exhibits the desired mechanical properties of low resistance, corrosion resistance, flexibility, and strength.
Like the primary stimulation lead 102, each secondary stimulation lead 104 comprises an elongated sheath body 132 having a proximal end 134 and a distal end 136, a plurality of terminals 138 (in this case, four) mounted to the proximal end 134 of the sheath body 132, a plurality of electrodes 140 (in this case, four) mounted to the distal end 136 of the sheath body 132, and a plurality of conductors (shown in Fig. 4) extending through the sheath body 132 and respectively connecting the electrodes 120 to the terminals 118. The sheath bodies 132 of the secondary stimulation leads 104 are similar to the sheath body 112 of the primary stimulation lead 102, with the exception that the distal ends 136 are tapered in only one direction. In this manner, the stimulation lead assembly 110, as illustrated in Fig. 2, forms a lower profile distal end to facilitate placement of the assembly 110 within the epidural space of the patient's spine. Like the sheath body 112 of the primary stimulation lead 102, the sheath bodies 132 of the secondary stimulation leads 104 may each have an optional lumen (not shown) for receiving a stylet (not shown) to facilitate percutaneous introduction of the secondary stimulation lead 104 within the epidural space of the patient's spine, as will be described in further detail below.
The terminals 118 and electrodes 120 of the secondary stimulation leads 104 are similar to the terminals 118 and electrodes 120 of the primary stimulation lead 102, with the exception that there are four sets of terminals 118 and electrodes 120 instead of three. Notably, the electrodes 120 of the secondary stimulation leads 104 face the same direction as the electrodes 140 of the primary stimulation leads 102, so that the entire stimulation lead assembly 110 is capable of focusing electrical energy in a single direction, as shown in Fig. 3. Also, as illustrated in Fig.
3, the electrodes 120/140 are arranged on the respective sheath bodies 112/132, such that the electrodes 140 of the secondary stimulation leads 104 are offset from the electrodes 120 of the primary stimulation lead 102 in the longitudinal direction, thereby preventing accidental shorting between adjacent electrodes when the assembly 110 is formed. Further details regarding the structure and composition of standard percutaneous stimulation leads are disclosed in U.S. Patent No.
6,216,045.
The primary stimulation lead 102 and the respective secondary stimulation leads 104 are configured to slidably engage each other to form the lead assembly 110 illustrated in Fig. 2. In particular, referring to Figs. 3-5, the primary stimulation lead 102 comprises a pair of circumferentially opposed slots 150 extending along the length of the sheath body 112. The slots 150 can be formed in the sheath body using any one of a variety of manners, but in the illustrated embodiment, the slots 150 are formed during the extrusion process. Alternatively, the slots 150 can be formed by embedding, or otherwise mounting, discrete slotted members (not shown) along the sheath body 112. In contrast, each of the secondary stimulation leads 104 comprises a rail 152 extending along the sheath body 132. Like the slots 150, the rail 152 can be formed on the sheath body 132 using any one of a variety of manners, such as forming the rail 152 during the extrusion process.
Alternatively, the rail 152 can be formed of a discrete member (not shown) that is bonded, or otherwise mounted, to the sheath body 132. In other embodiments, the primary stimulation lead 102 may have a pair of circumferentially opposed rails extending along its sheath body 112, while the secondary stimulation leads 104 may have slots 150 extending along their sheath bodies 132. In any event, the rails 152 and slots 150 are sized to snuggly engage each other in a sliding relationship, as best shown in Fig. 5.
Thus, it can be appreciated that the secondary stimulation leads 104 can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming the stimulation assembly 110 illustrated in Fig.
2. The opposing slots 150 of the primary stimulation lead 102 and the rails 152 of the secondary stimulation leads 104 are circumferentially offset ninety degrees from the centers of the respective electrodes 120. In this manner, all of the electrodes 120, which generally face in the same direction, as described above, are ensured to face in a direction perpendicular to the plane of the assembly 110, thereby maximizing transmission of the stimulation energy into the target neural tissue when the assembly 110 is fully implanted within the epidural space of the patient's spine.
Although a rail and slot arrangement has been disclosed as the preferred means of slidably engaging the primary and stimulation leads 102!104, other means of slidably engaging the leads can be provided. For example, instead of slots, the primary stimulation lead can have loop structures (not shown) that extend along the opposing sides the respective sheath body. The secondary stimulation leads 104 can then be introduced through the respective sets of loop structures in order to couple the leads together.
In the illustrated embodiment, the slots 150 have distal rail stops (not shown), i.e., the distal ends of the slots 150 terminate prior to the distal tip of the sheath body 112 to prevent the distal ends 136 of the secondary stimulation leads 104 from sliding distal to the distal end 116 of the primary stimulation lead 102.
Alternatively, the distal ends of the slots 150 may have chamfered openings 151, as illustrated in Fig. 13. In this manner, the distal ends of the secondary stimulation leads 104 will diverge from the distal end of the primary stimulation lead 102 when the leads 102/104 are slidably engaged with each other. That is, when the rail 152 of a secondary stimulation lead 104 is slid along the respective slot 150 of the primary stimulation lead 102, the distal end of the rail 152 will be diverted out of the chamfered opening 151 at the distal end of the slot 150, thereby expanding the footprint of the resultirig assembly 110, as illustrated in Fig. 14a. The secondary stimulation lead 104 may have a proximal rail stop (not shown) to prevent further sliding of the respective secondary stimulation lead 104 when fully deployed.
The distal ends of the secondary stimulation leads 104 can be pre-curved inward towards the primary stimulation lead 102, as illustrated in Fig. 14a, so that the distal ends of the secondary stimulation leads 104, when deployed from the primary stimulation lead 102, extend in a parallel direction with the distal end of the primary stimulation lead 102. The distal ends of the secondary stimulation leads 104 can be pre-curved in any one of a variety of manners. For example, as illustrated in Fig.
15a, a pre-curved resilient member 153 composed of a suitable material, such as nitinol, can be formed within the sheath body 132. Preferably, the cross-section of the resilient member 153 resembles of flat plate, so that the sheath body 132 consistently bends in a pre-defined plane, i.e., within the plane of the assembly 110.
Alternatively, as illustrated in Fig. 14b, the distal ends of the secondary stimulation leads 104 are not pre-curved, but rather normally exhibit a straight geometry after exiting slot 150 of the primary stimulation lead 102 (shown in phantom in Fig. 14b), such that the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102. Alternatively, the distal ends of the secondary stimulation leads 104 may not be resilient. In either case, the secondary stimulation lead 104 comprises a lumen 155 through which a curved stylet 157 is introduced, as illustrated in Fig. 15b. The distal end of the stylet 157 is curved, such that, when introduced through the lumen 155, the distal end of the respective stimulation lead 104 assumes a geometry that curves inward towards the primary stimulation lead 102, as illustrated in Fig. 14b. Differently curved stylets 157 can be used in order to provide the distal end of the secondary stimulation lead 104 with the desired curved geometry. Alternatively, rather than providing a curved stylet 157 and a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the distal end of the stylet 157 can be straight, so that its introduction through the lumen 157 straightens the pre-curved distal end of the secondary stimulation lead 104, as shown in phantom in Fig. 14b.
As another alternative, a steering mechanism can be used to control the shape of the secondary stimulation lead 104. In particular, as illustrated in Fig. 14c, the distal ends of the secondary stimulation leads 104 normally exhibit a straight geometry, in which case, the resilient member 153 is likewise formed into a straight geometry. As illustrated in Fig. 15c, the secondary stimulation lead 104 comprises a pullwire lumen 159 and an associated pullwire 161 mounted to the inside surface of the distal end of the resilient member 153. When the pullwire 161 is relaxed, the distal end of the secondary stimulation lead 104 assumes the straight geometry. In this case, the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102, as illustrated in Fig. 14c. In contrast, when the pullwire 161 is pulled, the distal end of the secondary stimulation lead 104 assumes a geometry (shown in phantom) that curves -inward towards the primary stimulation lead 102. Notably, the proximal-most portion of the distal ends of the secondary stimulation leads 104 does not contain the resilient member 153, so that the respective stimulation lead 104 bends at this portion when the pullwire 161 is pulled.
Rather than providing a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the pullwire 161 can be mounted to the outside surface of the distal end of the resilient member 153, such that relaxation of the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a curved geometry that converges towards the primary stimulation lead 102, whereas the application of tension on the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a lesser curved or straight geometry that diverges from the primary stimulation lead 102.
As still another alternative, a portion of the secondary stimulation lead 104 may not have a rail, so that it bows outward after the primary stimulation lead 102 and secondary stimulation lead 104 are fully engaged, as illustrated in Fig.
14d. As best seen in Figs. 15d-f , the rail 152 extends along the distal-most and proximal-most portions of the distal end of the second stimulation lead 104, but does not extend along a medial-portion of the distal end of the second stimulation lead 104.
As a result, after the distal end of the respective rail 152 (i.e., the rail 152 located on the distal-most portion of the second stimulation lead 104) abuts the distal rail stop (not shown) in the corresponding slot 150, further distal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial-portion, which is not engaged with the slot 150 of the primary stimulation lead 102, to bow outward from a straight geometry (shown in phantom). In contrast, proximal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial-portion to return from the bowed geometry back to its straight geometry.
It should be noted that although the assemblies 110 illustrated in Figs. 2 and 14a-d are formed of three stimulation leads, less or more than three stimulation leads can be used. For example, if an assembly formed only of two stimulation leads is desired, only one slot 150 on the primary stimulation lead 102 is required. In this case, the primary stimulation lead 102 may only have one slot 150 formed along one side of the respective body 112, or alternatively, if the primary stimulation lead 102 comprises two opposing slots 150, only one will be used to couple the lone secondary stimulation lead 104 thereto. On the other hand, if an assembly formed of more than three stimulation leads is desired, the secondary stimulation leads may have a pair of circumferentially opposed rails 152. For example, if there are five stimulation leads, two secondary stimulation leads 103 (which are similar to the secondary stimulation leads 104, but with a pair of circumferentially opposing rails 152) can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming a partial assembly similar to that illustrated in Fig. 3. Then, two additional secondary stimulation leads 105 (which are similar to secondary stimulation leads 105, but have a pair of circumferentially opposed slots 150) can be coupled to the secondary stimulation leads 105 by sliding the slots 150 of the additional secondary stimulation leads 102 along the respective rails 152, thereby forming a full assembly 160, as illustrated in Figs. 6 and 7.
Referring back to Fig. 1, the implantable stimulation source 106 is designed to deliver electrical pulses to the stimulation leads 102/104 in accordance with programmed parameters. In one embodiment, the stimulation source 106 is programmed to output electrical pulses having amplitudes varying from 0.1 to volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates varying from 2 to 2500 Hertz. In the illustrated embodiment, the stimulation source takes the form of a totally self-contained generator, which once implanted, may be activated and controlled by an outside telemetry source, e.g., a small magnet.
In this case, the pulse generator has an internal power source that limits the life of the pulse generator to a few years, and after the power source is expended, the pulse generator must be replaced. Generally, these types of stimulation sources 106 may be implanted within the chest or abdominal region beneath the skin of the patient.
Alternatively, the implantable stimulation source 106 may take the form of a passive receiver that receives radio frequency (RF) signals from an external transmitter worn by the patient. In this scenario, the life of the stimulation source 106 is virtually unlimited, since the stimulation signals originate from the external transmitter. Like the self-contained generators, the receivers of these types of stimulation sources 106 can be implanted within the chest or abdominal region beneath the skin of the patient. The receivers may also be suitable for implantation behind the ear of the patient, in which case, the external transmitter may be worn on the ear of the patient in a manner similar to that of a hearing aid.
Stimulation sources, such as those just described, are commercially available from Advanced Neuromodulation Systems, Inc., located in Plano, Texas, and Medtronic, Inc., located in Minneapolis, Minnesota.
The optional extension lead 108 comprises an elongated sheath body 144 having a proximal end 146 and a distal end 148, much like the sheath bodies 112/132 of the stimulation leads 102/104, a distal adapter 154 coupled to the distal end 148 of the sheath body 144, a connector 156 coupled to the proximal end 146 of the sheath body 144, and a plurality of electrical conductors (not shown) extending through the sheath body 144. The length of the extension lead 108 is sufficient to extend from the spine of the patient, where the proximal ends of the implanted stimulation leads 102/104 protrude from to the implantation site of the stimulation source 106-typically somewhere in the chest or abdominal region. The distal adapter 154 is configured to receive the proximal ends of the stimulation leads 102/104, and the proximal connector 156 is configured to couple to the stimulation source 106.
Having described the stimulation lead kit 100, its installation and use in treating chronic pain will now be described with reference to Figs. 8A-8D.
After the patient has been prepared (which may involve testing the efficacy of spinal cord stimulation on the patient, and, once determining that the patient can be effectively treated with spinal cord stimulation, identifying and marking the appropriate vertebral intervals on the patient's skin and applying a local anesthetic to this region), a needle 10, such as, e.g., a Touhy needle, is inserted through the patient's skin 12 between the desired vertebrae 14, and into the epidural space 16 within the spine at a position inferior to target stimulation site 18 (Fig. 8A). In the illustrated method, the Touhy needle 10 will serve as the primary delivery mechanism for the primary stimulation lead 102. Alternatively, if an optional introduces (not shown) is used, a guide wire (not shown) is introduced through the needle 10 and advanced to or near the target stimulation site 18. The needle 10 is removed, the introduces is then introduced over the guide wire and advanced to the target stimulation site 18, and the guide wire is then withdrawn. In this case, the introduces will serve as the primary delivery mechanism for the primary stimulation lead 102.
After the deliver mechanism is in place, the primary stimulation lead 102 is then inserted through the needle or the introduces (whichever is in place), and positioned in the epidural space at the target stimulation site 18, with the electrodes 120 facing the dural layer 20 surrounding the spinal cord 22 (Fig. 8B). If the primary stimulation lead 102 has a stylet lumen, a stylet can be used to provide additional axial stiffness and to facilitate control. Next, the needle 10 or introduces is removed, and one of the secondary stimulation leads 104 is delivered through the percutaneous opening 24 left by the removal of the needle 10, and into the epidural space 16 by slidably engaging the secondary stimulation lead 104 along the primary stimulation lead 102 (Fig. 8C). In particular, the rail 152 of the secondary stimulation lead 104 is inserted into the corresponding slot 150 of the primary stimulation lead 102, and the secondary stimulation lead 104 is pushed until the distal end of the rail 152 abuts the distal end of the slot 150, thereby signifying that the secondary stimulation lead 104 is fully engaged with the primary stimulation lead 102 (with the electrodes 120/140 of the stimulation leads 102/104 adjacent, but offset from, each other) and is in its proper location within the epidural space 16 of the patient. The other secondary stimulation lead 104 is then delivered into the epidural space by slidably engaging it along the primary stimulation lead 102 in the same manner, thereby completing the stimulation lead assembly 110 (Fig. 8D). If the secondary stimulation leads 104 have stylet lumens, a stylet can be used to provide additional axial stiffness and to facilitate control. Once the assembly 110 is completed, the electrodes 120/140 will span the midline of the spinal,cord 22, much like the electrodes of a standard surgical lead do.
Next, the proximal ends of the stimulation leads 102/104 are connected to a tester (not shown), which is then operated in a standard manner to confirm proper location of the stimulation lead assembly 110 and to adjust the stimulation parameters for optimal pain relief. Once this optimization process has been completed, the tester is disconnected from the stimulation leads 102/104, which are then anchored in place using standard lead anchors (not shown). Next, the stimulation lead assembly 110 is coupled to the stimulation source 106 and implantation is completed (not shown). In particular, a subcutaneous pocket is created in the patient's abdominal area for implantation of the stimulation source 106, and a tunnel is subcutaneously formed between the spine region and the subcutaneous pocket. The optional lead extension 108 is passed through the tunnel, after which the adapter 154 of the extension 108 is connected to the proximal ends of the stimulation leads 102/104 and the connector 156 of the lead extension 108 is connected to the stimulation source 106. The stimulation source 106 is programmed and tested, and then placed within the subcutaneous pocket, after which all incisions are closed to effect implantation of the stimulation lead assembly 110 and stimulation source 106. The stimulation source 106 can then be operated to convey stimulation energy from the stimulation source 106 to the electrodes 120/140 of the stimulation lead assembly 110, where it is, in turn, conveyed into the neural tissue for pain relief.
If necessary or desired, e.g., if the electrodes 120/140 malfunction or stimulation otherwise ceases to provide therapeutic benefit, the stimulation lead assembly can be subsequently retrieved from the patient's spine by removing the assembly 110 at the same time or by removing the assembly one stimulation lead 1021104 at a time by slidably disengaging the stimulation leads 102/104. In the case of the assembly 110 illustrated in Fig. 14, the rail and slot arrangement will pull the deployed distal end of the secondary stimulation leads 104 along side of the primary stimulation lead 102 when retrieved.
It can be appreciated that the relatively large footprint made by the stimulation lead assembly 110, much like a prior art surgical lead, provides a more stable platform for the electrodes 120!140. Also, like a prior art surgical lead, the electrodes 120/140 face in a single direction, thereby focusing the stimulation energy into the affected neural tissue where it is needed. Unlike a surgical lead, however, the stimulation lead assembly 110 can be percutaneously delivered into the patient's spine in a minimally invasive and relatively pain-free manner, without requiring extensive patient recovery.
Referring now to Fig. 9, a modular stimulation lead kit 200 arranged in accordance with another embodiment of the invention is shown. The kit 200 is similar to the previously described kit 100, with the exception that the kit comprises secondary stimulation leads 204 that minimize the profile of the resulting assembly (shown in Fig. 10), as it exits the spine of the patient. In particular, each secondary stimulation lead 204 comprises a shortened sheath body 232, electrodes 240 mounted to the sheath body 232, electrical conductors 242 extending from the sheath body 232, and a connector 244 that receives the proximal ends of the electrical conductors 242. The connector 244 comprises a plurality of terminals 238 that are similar to the previously described lead terminals 138. The sheath body 232 is composed of the same material and has the same general shape as the sheath body 132 of the previously described secondary stimulation lead 104. The sheath body 232, as illustrated in Fig. 9, however, is much shorter, so that it can be entirely received within the epidural space of the patient, i.e., the sheath body 232 will not extend out of the patient's back when fully deployed within the epidural space. The electrical conductors 242, because they are exposed, are preferably composed of an electrically insulative material.
The kit 200 further comprises a pusher 214 that can be used to facilitate introduction of the respective secondary stimulation lead 204 along the primary stimulation lead 102 once the entire sheath body 232 of the secondary stimulation lead 204 is within the patient's back. The pusher 214 comprises a cylindrical rod 216 having a distal tip 218 and a proximal end 220, and a handle 222 mounted on the proximal end 220 of the rod 216. The distal tip 218 of the rod 216 is adapted to be received within an opening 224 (shown in Fig. 11 ) at the proximal end of the sheath body 232, thereby facilitating stable engagement between the pusher 214 and respective secondary stimulation lead 204.
The kit 200 can be installed and used in the same manner as the previously described kit 100 in treating chronic pain. In particular, the patient is prepared and the primary stimulation lead 102 is delivered into the epidural space 16 of the patient's spine, so that the electrodes 120 are placed adjacent the target stimulation "site 18 in the same manner described above with respect to Fig. 8A and 8B.
One of the secondary stimulation leads 204 is then delivered into the epidural space 16 in the same manner as the secondary stimulation lead 104 described above was delivered, with the exception that the pusher 214 is used to advance the secondary stimulation lead 204 along the primary stimulation lead 102 until fully deployed within the epidural space 16 (Fig. 12A). The remaining stimulation lead 204 is delivered into the epidural space 16 in the same manner to complete the stimulation lead assembly 210 (Fig. 12B).
Notably, because the percutaneous opening 24 need only support, at most, two sheath bodies at one time, it can be made smaller, or alternatively, additional stimulation leads with shortened sheath bodies can be introduced within the epidural space 16 without increasing the size of the percutaneous opening. After the stimulation lead assembly 210 has been formed within the epidural space, it is tested and optimized. The extension lead 108 is then connected between the stimulation leads 102/204 and the stimulation source 106, and the incisions are closed to fully implant the system, as previously described above.
Referring now to Fig. 16, an alternative embodiment of a secondary stimulation lead 304 engaged with one side of the primary stimulation 102 is illustrated. Although not shown, another secondary stimulation lead 304 can be engaged with the opposite side of the primary stimulation lead 102. The secondary stimulation lead 304 is similar to the previously described secondary stimulation lead 104, with the exception that the secondary stimulation lead 304 comprises a flap 303 on which the electrodes 140 are mounted. The secondary stimulation lead 304 can, alternatively, have a shortened sheath body much like the secondary stimulation lead 204 illustrated in Fig. 9. The flap 303 is designed to be constrained by the primary stimulation lead 102 to facilitate percutaneous delivery of the secondary stimulation lead 102, and released by the primary stimulation lead 102 to deploy the electrodes 140 into contact with the neural tissue.
In particular, the edge of the flap 303 comprises a coupling mechanism 305 that is designed to fit snugly within the respective slot 150 of the primary stimulation lead 102, along with the rail 152 of the secondary stimulation lead 102, when the secondary stimulation lead 304 is slidably engaged with the primary stimulation lead 102, as illustrated in Fig. 17. As the rail 152 of the secondary stimulation lead 102 exits the slot 150 of the primary stimulation lead 102, however, the coupling mechanism 305 of the flap 303 will release from the slot 150, thereby allowing the flap 303 to deploy, placing the electrodes 140 into contact with the underlying tissue, as illustrated in Fig. 18. It should be noted, that, when the secondary stimulation lead 304 is used in the kit 100 or kit 200, the slots 150 in the primary stimulation lead 102 will not terminate as hereinbefore described, but will rather open up at the distal tip of the primary stimulation lead 102, so that the flap 303 can exit the respective slot 150 and be released by the primary stimulation lead 102.
Installation and use of the secondary stimulation lead 304 in forming the stimulation lead assembly 110 illustrated in Fig. 2, or alternatively the stimulation lead assembly 210 illustrated in Fig. 10, is similar that previously described above.
Although in all of the previous embodiments, the primary stimulation lead 102 was used to provide a means of guiding the secondary stimulation leads 104 into the percutaneous opening within the patient and adjacent the target tissue region, as well as to provide a means of stimulating the tissue region, a guide member similar to the primary stimulation lead 102, but lacking stimulation capability, can be alternatively used to similarly guide the secondary stimulation leads 104 through the percutaneous opening to the target tissue region. In this case, only the secondary stimulation leads 104 will be used to stimulate tissue.
Fig. 10 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 9;
Fig. 11 is a cross-sectional view of the secondary stimulation lead of Fig.
10, taken along the line 11-11;
Figs. 12A-12B are various views illustrating the installation of the kit of Fig. 9 into a patient's spine;
Fig. 13 is a partially cutaway top view of the distal end of an alternative primary stimulation lead that can be used in kit of Fig. 1;
Fig. 14a is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig.
13 is used, wherein the secondary stimulation leads are shown in a normally curved geometry that converges towards the primary stimulation lead;
Fig. 15a is a cross-sectional view of the stimulation lead assembly of Fig.
14a, taken along the line 15a-15a;
Fig. 14b is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig.
13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a stylet is introduced;
Fig. 15b is a cross-sectional view of the stimulation lead assembly of Fig.
14b, taken along the line 15b-15b;
Fig. 14c is a cutaway top view of another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a pullwire is tensioned;
Fig. 15c is a cross-sectional view of the stimulation lead assembly of Fig.
14c, taken along the line 15c-15c;
Fig. 14d is a cutaway top view of still another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 3 is used, wherein the secondary stimulation leads can be placed into a curved geometry that bows away from the primary stimulation lead;
Fig. 15d is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15d-15d;
Fig. 15e is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15e-15e;
Fig. 15f is a cross-sectional view of the stimulation lead assembly of Fig.
14d, taken along the line 15f-15f;
Fig. 16 is a cutaway top view of an alternative stimulation lead assembly;
Fig. 17 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing an electrode flap of a secondary stimulation lead constrained by the primary stimulation lead; and Fig. 18 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing the electrode flap of the secondary stimulation lead released by the primary stimulation lead.
DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS
Referring now to Fig. 1, a modular stimulation lead kit 100 arranged in accordance with one embodiment of the invention, generally comprises a primary stimulation lead 102 and two secondary stimulation leads 104, which are configured to be percutaneously delivered and implanted into the epidural space of a patient's spine, an implantable electrical stimulation source 106 configured for delivering stimulation energy to the stimulation leads 102/104, and an optional extension lead 105 configured for connecting the stimulation leads 102/104 to the remotely implanted stimulation source 106. As will be described in further detail below, the secondary stimulation leads 104 can be attached to the primary stimulation lead 102 to form a modularized stimulation lead assembly 110, as illustrated in Fig. 2.
It should be noted that although the kit 100 illustrated in Fig. 1 is described herein as being used in spinal cord stimulation (SCS) for the treatment of chronic pain, the kit 100, or a modification of the kit 100, can be used in an SCS
procedure to treat other ailments, or can used in other applications other than SCS
procedures, such as peripheral nervous system stimulation, sacral root stimulation, and brain tissue stimulation, including cortical and deep brain stimulation. In the latter case, the stimulation leads 102/104 can be delivered through a miniature cranial burr hole into the brain tissue.
The primary stimulation lead 102 comprises an elongated sheath body 112 having a proximal end 114 and a distal end 116. The sheath body 112 is composed of a suitably flexible material (such as polyurethane, silicone, etc.), which may either be resilient or non-resilient, and may be formed via an extrusion process or by any other suitable means. The distal end 116 of the sheath body 112 is soft and tapered to prevent injury to nerve roots that exit the spinal cord when delivered into the epidural space of the patient's spine. In the illustrated embodiment, the sheath body 112 is cylindrically-shaped and sized to fit through a Touhy-like needle (not shown).
In this case, the diameter of the sheath body 112 is preferably less than 5 mm to allow it to be percutaneously introduced through a needle. More preferably, the diameter of the sheath body 112 is within the range of 1 mm to 3 mm, so that the primary stimulation lead 102, along with the secondary stimulation leads 104 described below, can comfortably fit within the epidural space of the patient.
The sheath body 112 may have other cross-sectional geometries, such as elliptical, rectangular, triangular, etc. If rectangular, the width of the primary stimulation lead 102 can be up to 5 mm, since the width of an epidural space is greater than its height. The sheath body 112 may have an optional lumen (not shown) for receiving a stylet (not shown) that axially stiffens the sheath body 112 to facilitate percutaneous introduction of the primary stimulation lead 102 within the epidural space of the patient's spine, as will be described in further detail below.
The primary stimulation lead 102 further comprises a plurality of terminals (in this case, three) mounted on the proximal end 114 of the sheath body 112, and a plurality of stimulation elements, and in particular electrodes 120 (in this case, three), mounted on the distal end 116 of the sheath body 112. The terminals 118 are formed of ring-shaped elements composed of a suitable biocompatible metallic material, such as platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials, and can be mounted to the sheath body 112 in an interference fit arrangement.
In the illustrated embodiment, the electrodes 120 are formed on one circumferential side of the sheath body 112 (shown best in Fig. 3) in order to focus stimulation energy in one direction, thereby maximizing energy efficiency. The electrodes 120 can be formed onto the sheath body 112 using known deposition processes, such as sputtering, vapor deposition, ion beam deposition, electroplating over a deposited seed layer, or a combination of these processes.
Alternatively, the electrodes 120 can be formed onto the sheath body 112 as a thin sheet or foil of electrically conductive metal affixed to the wall of the sheath body 112. The electrodes 120 can be composed of the same electrically conductive and biocompatible material as the terminals 118, e.g., platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials.
The primary stimulation lead 102 further comprises a plurality of conductors 122 (shown in Fig. 3) extending through the sheath body 112 and connecting each electrode 120 with a respective terminal 118. The conductors 122 are composed of a suitably electrically conductive material that exhibits the desired mechanical properties of low resistance, corrosion resistance, flexibility, and strength.
Like the primary stimulation lead 102, each secondary stimulation lead 104 comprises an elongated sheath body 132 having a proximal end 134 and a distal end 136, a plurality of terminals 138 (in this case, four) mounted to the proximal end 134 of the sheath body 132, a plurality of electrodes 140 (in this case, four) mounted to the distal end 136 of the sheath body 132, and a plurality of conductors (shown in Fig. 4) extending through the sheath body 132 and respectively connecting the electrodes 120 to the terminals 118. The sheath bodies 132 of the secondary stimulation leads 104 are similar to the sheath body 112 of the primary stimulation lead 102, with the exception that the distal ends 136 are tapered in only one direction. In this manner, the stimulation lead assembly 110, as illustrated in Fig. 2, forms a lower profile distal end to facilitate placement of the assembly 110 within the epidural space of the patient's spine. Like the sheath body 112 of the primary stimulation lead 102, the sheath bodies 132 of the secondary stimulation leads 104 may each have an optional lumen (not shown) for receiving a stylet (not shown) to facilitate percutaneous introduction of the secondary stimulation lead 104 within the epidural space of the patient's spine, as will be described in further detail below.
The terminals 118 and electrodes 120 of the secondary stimulation leads 104 are similar to the terminals 118 and electrodes 120 of the primary stimulation lead 102, with the exception that there are four sets of terminals 118 and electrodes 120 instead of three. Notably, the electrodes 120 of the secondary stimulation leads 104 face the same direction as the electrodes 140 of the primary stimulation leads 102, so that the entire stimulation lead assembly 110 is capable of focusing electrical energy in a single direction, as shown in Fig. 3. Also, as illustrated in Fig.
3, the electrodes 120/140 are arranged on the respective sheath bodies 112/132, such that the electrodes 140 of the secondary stimulation leads 104 are offset from the electrodes 120 of the primary stimulation lead 102 in the longitudinal direction, thereby preventing accidental shorting between adjacent electrodes when the assembly 110 is formed. Further details regarding the structure and composition of standard percutaneous stimulation leads are disclosed in U.S. Patent No.
6,216,045.
The primary stimulation lead 102 and the respective secondary stimulation leads 104 are configured to slidably engage each other to form the lead assembly 110 illustrated in Fig. 2. In particular, referring to Figs. 3-5, the primary stimulation lead 102 comprises a pair of circumferentially opposed slots 150 extending along the length of the sheath body 112. The slots 150 can be formed in the sheath body using any one of a variety of manners, but in the illustrated embodiment, the slots 150 are formed during the extrusion process. Alternatively, the slots 150 can be formed by embedding, or otherwise mounting, discrete slotted members (not shown) along the sheath body 112. In contrast, each of the secondary stimulation leads 104 comprises a rail 152 extending along the sheath body 132. Like the slots 150, the rail 152 can be formed on the sheath body 132 using any one of a variety of manners, such as forming the rail 152 during the extrusion process.
Alternatively, the rail 152 can be formed of a discrete member (not shown) that is bonded, or otherwise mounted, to the sheath body 132. In other embodiments, the primary stimulation lead 102 may have a pair of circumferentially opposed rails extending along its sheath body 112, while the secondary stimulation leads 104 may have slots 150 extending along their sheath bodies 132. In any event, the rails 152 and slots 150 are sized to snuggly engage each other in a sliding relationship, as best shown in Fig. 5.
Thus, it can be appreciated that the secondary stimulation leads 104 can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming the stimulation assembly 110 illustrated in Fig.
2. The opposing slots 150 of the primary stimulation lead 102 and the rails 152 of the secondary stimulation leads 104 are circumferentially offset ninety degrees from the centers of the respective electrodes 120. In this manner, all of the electrodes 120, which generally face in the same direction, as described above, are ensured to face in a direction perpendicular to the plane of the assembly 110, thereby maximizing transmission of the stimulation energy into the target neural tissue when the assembly 110 is fully implanted within the epidural space of the patient's spine.
Although a rail and slot arrangement has been disclosed as the preferred means of slidably engaging the primary and stimulation leads 102!104, other means of slidably engaging the leads can be provided. For example, instead of slots, the primary stimulation lead can have loop structures (not shown) that extend along the opposing sides the respective sheath body. The secondary stimulation leads 104 can then be introduced through the respective sets of loop structures in order to couple the leads together.
In the illustrated embodiment, the slots 150 have distal rail stops (not shown), i.e., the distal ends of the slots 150 terminate prior to the distal tip of the sheath body 112 to prevent the distal ends 136 of the secondary stimulation leads 104 from sliding distal to the distal end 116 of the primary stimulation lead 102.
Alternatively, the distal ends of the slots 150 may have chamfered openings 151, as illustrated in Fig. 13. In this manner, the distal ends of the secondary stimulation leads 104 will diverge from the distal end of the primary stimulation lead 102 when the leads 102/104 are slidably engaged with each other. That is, when the rail 152 of a secondary stimulation lead 104 is slid along the respective slot 150 of the primary stimulation lead 102, the distal end of the rail 152 will be diverted out of the chamfered opening 151 at the distal end of the slot 150, thereby expanding the footprint of the resultirig assembly 110, as illustrated in Fig. 14a. The secondary stimulation lead 104 may have a proximal rail stop (not shown) to prevent further sliding of the respective secondary stimulation lead 104 when fully deployed.
The distal ends of the secondary stimulation leads 104 can be pre-curved inward towards the primary stimulation lead 102, as illustrated in Fig. 14a, so that the distal ends of the secondary stimulation leads 104, when deployed from the primary stimulation lead 102, extend in a parallel direction with the distal end of the primary stimulation lead 102. The distal ends of the secondary stimulation leads 104 can be pre-curved in any one of a variety of manners. For example, as illustrated in Fig.
15a, a pre-curved resilient member 153 composed of a suitable material, such as nitinol, can be formed within the sheath body 132. Preferably, the cross-section of the resilient member 153 resembles of flat plate, so that the sheath body 132 consistently bends in a pre-defined plane, i.e., within the plane of the assembly 110.
Alternatively, as illustrated in Fig. 14b, the distal ends of the secondary stimulation leads 104 are not pre-curved, but rather normally exhibit a straight geometry after exiting slot 150 of the primary stimulation lead 102 (shown in phantom in Fig. 14b), such that the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102. Alternatively, the distal ends of the secondary stimulation leads 104 may not be resilient. In either case, the secondary stimulation lead 104 comprises a lumen 155 through which a curved stylet 157 is introduced, as illustrated in Fig. 15b. The distal end of the stylet 157 is curved, such that, when introduced through the lumen 155, the distal end of the respective stimulation lead 104 assumes a geometry that curves inward towards the primary stimulation lead 102, as illustrated in Fig. 14b. Differently curved stylets 157 can be used in order to provide the distal end of the secondary stimulation lead 104 with the desired curved geometry. Alternatively, rather than providing a curved stylet 157 and a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the distal end of the stylet 157 can be straight, so that its introduction through the lumen 157 straightens the pre-curved distal end of the secondary stimulation lead 104, as shown in phantom in Fig. 14b.
As another alternative, a steering mechanism can be used to control the shape of the secondary stimulation lead 104. In particular, as illustrated in Fig. 14c, the distal ends of the secondary stimulation leads 104 normally exhibit a straight geometry, in which case, the resilient member 153 is likewise formed into a straight geometry. As illustrated in Fig. 15c, the secondary stimulation lead 104 comprises a pullwire lumen 159 and an associated pullwire 161 mounted to the inside surface of the distal end of the resilient member 153. When the pullwire 161 is relaxed, the distal end of the secondary stimulation lead 104 assumes the straight geometry. In this case, the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102, as illustrated in Fig. 14c. In contrast, when the pullwire 161 is pulled, the distal end of the secondary stimulation lead 104 assumes a geometry (shown in phantom) that curves -inward towards the primary stimulation lead 102. Notably, the proximal-most portion of the distal ends of the secondary stimulation leads 104 does not contain the resilient member 153, so that the respective stimulation lead 104 bends at this portion when the pullwire 161 is pulled.
Rather than providing a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the pullwire 161 can be mounted to the outside surface of the distal end of the resilient member 153, such that relaxation of the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a curved geometry that converges towards the primary stimulation lead 102, whereas the application of tension on the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a lesser curved or straight geometry that diverges from the primary stimulation lead 102.
As still another alternative, a portion of the secondary stimulation lead 104 may not have a rail, so that it bows outward after the primary stimulation lead 102 and secondary stimulation lead 104 are fully engaged, as illustrated in Fig.
14d. As best seen in Figs. 15d-f , the rail 152 extends along the distal-most and proximal-most portions of the distal end of the second stimulation lead 104, but does not extend along a medial-portion of the distal end of the second stimulation lead 104.
As a result, after the distal end of the respective rail 152 (i.e., the rail 152 located on the distal-most portion of the second stimulation lead 104) abuts the distal rail stop (not shown) in the corresponding slot 150, further distal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial-portion, which is not engaged with the slot 150 of the primary stimulation lead 102, to bow outward from a straight geometry (shown in phantom). In contrast, proximal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial-portion to return from the bowed geometry back to its straight geometry.
It should be noted that although the assemblies 110 illustrated in Figs. 2 and 14a-d are formed of three stimulation leads, less or more than three stimulation leads can be used. For example, if an assembly formed only of two stimulation leads is desired, only one slot 150 on the primary stimulation lead 102 is required. In this case, the primary stimulation lead 102 may only have one slot 150 formed along one side of the respective body 112, or alternatively, if the primary stimulation lead 102 comprises two opposing slots 150, only one will be used to couple the lone secondary stimulation lead 104 thereto. On the other hand, if an assembly formed of more than three stimulation leads is desired, the secondary stimulation leads may have a pair of circumferentially opposed rails 152. For example, if there are five stimulation leads, two secondary stimulation leads 103 (which are similar to the secondary stimulation leads 104, but with a pair of circumferentially opposing rails 152) can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming a partial assembly similar to that illustrated in Fig. 3. Then, two additional secondary stimulation leads 105 (which are similar to secondary stimulation leads 105, but have a pair of circumferentially opposed slots 150) can be coupled to the secondary stimulation leads 105 by sliding the slots 150 of the additional secondary stimulation leads 102 along the respective rails 152, thereby forming a full assembly 160, as illustrated in Figs. 6 and 7.
Referring back to Fig. 1, the implantable stimulation source 106 is designed to deliver electrical pulses to the stimulation leads 102/104 in accordance with programmed parameters. In one embodiment, the stimulation source 106 is programmed to output electrical pulses having amplitudes varying from 0.1 to volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates varying from 2 to 2500 Hertz. In the illustrated embodiment, the stimulation source takes the form of a totally self-contained generator, which once implanted, may be activated and controlled by an outside telemetry source, e.g., a small magnet.
In this case, the pulse generator has an internal power source that limits the life of the pulse generator to a few years, and after the power source is expended, the pulse generator must be replaced. Generally, these types of stimulation sources 106 may be implanted within the chest or abdominal region beneath the skin of the patient.
Alternatively, the implantable stimulation source 106 may take the form of a passive receiver that receives radio frequency (RF) signals from an external transmitter worn by the patient. In this scenario, the life of the stimulation source 106 is virtually unlimited, since the stimulation signals originate from the external transmitter. Like the self-contained generators, the receivers of these types of stimulation sources 106 can be implanted within the chest or abdominal region beneath the skin of the patient. The receivers may also be suitable for implantation behind the ear of the patient, in which case, the external transmitter may be worn on the ear of the patient in a manner similar to that of a hearing aid.
Stimulation sources, such as those just described, are commercially available from Advanced Neuromodulation Systems, Inc., located in Plano, Texas, and Medtronic, Inc., located in Minneapolis, Minnesota.
The optional extension lead 108 comprises an elongated sheath body 144 having a proximal end 146 and a distal end 148, much like the sheath bodies 112/132 of the stimulation leads 102/104, a distal adapter 154 coupled to the distal end 148 of the sheath body 144, a connector 156 coupled to the proximal end 146 of the sheath body 144, and a plurality of electrical conductors (not shown) extending through the sheath body 144. The length of the extension lead 108 is sufficient to extend from the spine of the patient, where the proximal ends of the implanted stimulation leads 102/104 protrude from to the implantation site of the stimulation source 106-typically somewhere in the chest or abdominal region. The distal adapter 154 is configured to receive the proximal ends of the stimulation leads 102/104, and the proximal connector 156 is configured to couple to the stimulation source 106.
Having described the stimulation lead kit 100, its installation and use in treating chronic pain will now be described with reference to Figs. 8A-8D.
After the patient has been prepared (which may involve testing the efficacy of spinal cord stimulation on the patient, and, once determining that the patient can be effectively treated with spinal cord stimulation, identifying and marking the appropriate vertebral intervals on the patient's skin and applying a local anesthetic to this region), a needle 10, such as, e.g., a Touhy needle, is inserted through the patient's skin 12 between the desired vertebrae 14, and into the epidural space 16 within the spine at a position inferior to target stimulation site 18 (Fig. 8A). In the illustrated method, the Touhy needle 10 will serve as the primary delivery mechanism for the primary stimulation lead 102. Alternatively, if an optional introduces (not shown) is used, a guide wire (not shown) is introduced through the needle 10 and advanced to or near the target stimulation site 18. The needle 10 is removed, the introduces is then introduced over the guide wire and advanced to the target stimulation site 18, and the guide wire is then withdrawn. In this case, the introduces will serve as the primary delivery mechanism for the primary stimulation lead 102.
After the deliver mechanism is in place, the primary stimulation lead 102 is then inserted through the needle or the introduces (whichever is in place), and positioned in the epidural space at the target stimulation site 18, with the electrodes 120 facing the dural layer 20 surrounding the spinal cord 22 (Fig. 8B). If the primary stimulation lead 102 has a stylet lumen, a stylet can be used to provide additional axial stiffness and to facilitate control. Next, the needle 10 or introduces is removed, and one of the secondary stimulation leads 104 is delivered through the percutaneous opening 24 left by the removal of the needle 10, and into the epidural space 16 by slidably engaging the secondary stimulation lead 104 along the primary stimulation lead 102 (Fig. 8C). In particular, the rail 152 of the secondary stimulation lead 104 is inserted into the corresponding slot 150 of the primary stimulation lead 102, and the secondary stimulation lead 104 is pushed until the distal end of the rail 152 abuts the distal end of the slot 150, thereby signifying that the secondary stimulation lead 104 is fully engaged with the primary stimulation lead 102 (with the electrodes 120/140 of the stimulation leads 102/104 adjacent, but offset from, each other) and is in its proper location within the epidural space 16 of the patient. The other secondary stimulation lead 104 is then delivered into the epidural space by slidably engaging it along the primary stimulation lead 102 in the same manner, thereby completing the stimulation lead assembly 110 (Fig. 8D). If the secondary stimulation leads 104 have stylet lumens, a stylet can be used to provide additional axial stiffness and to facilitate control. Once the assembly 110 is completed, the electrodes 120/140 will span the midline of the spinal,cord 22, much like the electrodes of a standard surgical lead do.
Next, the proximal ends of the stimulation leads 102/104 are connected to a tester (not shown), which is then operated in a standard manner to confirm proper location of the stimulation lead assembly 110 and to adjust the stimulation parameters for optimal pain relief. Once this optimization process has been completed, the tester is disconnected from the stimulation leads 102/104, which are then anchored in place using standard lead anchors (not shown). Next, the stimulation lead assembly 110 is coupled to the stimulation source 106 and implantation is completed (not shown). In particular, a subcutaneous pocket is created in the patient's abdominal area for implantation of the stimulation source 106, and a tunnel is subcutaneously formed between the spine region and the subcutaneous pocket. The optional lead extension 108 is passed through the tunnel, after which the adapter 154 of the extension 108 is connected to the proximal ends of the stimulation leads 102/104 and the connector 156 of the lead extension 108 is connected to the stimulation source 106. The stimulation source 106 is programmed and tested, and then placed within the subcutaneous pocket, after which all incisions are closed to effect implantation of the stimulation lead assembly 110 and stimulation source 106. The stimulation source 106 can then be operated to convey stimulation energy from the stimulation source 106 to the electrodes 120/140 of the stimulation lead assembly 110, where it is, in turn, conveyed into the neural tissue for pain relief.
If necessary or desired, e.g., if the electrodes 120/140 malfunction or stimulation otherwise ceases to provide therapeutic benefit, the stimulation lead assembly can be subsequently retrieved from the patient's spine by removing the assembly 110 at the same time or by removing the assembly one stimulation lead 1021104 at a time by slidably disengaging the stimulation leads 102/104. In the case of the assembly 110 illustrated in Fig. 14, the rail and slot arrangement will pull the deployed distal end of the secondary stimulation leads 104 along side of the primary stimulation lead 102 when retrieved.
It can be appreciated that the relatively large footprint made by the stimulation lead assembly 110, much like a prior art surgical lead, provides a more stable platform for the electrodes 120!140. Also, like a prior art surgical lead, the electrodes 120/140 face in a single direction, thereby focusing the stimulation energy into the affected neural tissue where it is needed. Unlike a surgical lead, however, the stimulation lead assembly 110 can be percutaneously delivered into the patient's spine in a minimally invasive and relatively pain-free manner, without requiring extensive patient recovery.
Referring now to Fig. 9, a modular stimulation lead kit 200 arranged in accordance with another embodiment of the invention is shown. The kit 200 is similar to the previously described kit 100, with the exception that the kit comprises secondary stimulation leads 204 that minimize the profile of the resulting assembly (shown in Fig. 10), as it exits the spine of the patient. In particular, each secondary stimulation lead 204 comprises a shortened sheath body 232, electrodes 240 mounted to the sheath body 232, electrical conductors 242 extending from the sheath body 232, and a connector 244 that receives the proximal ends of the electrical conductors 242. The connector 244 comprises a plurality of terminals 238 that are similar to the previously described lead terminals 138. The sheath body 232 is composed of the same material and has the same general shape as the sheath body 132 of the previously described secondary stimulation lead 104. The sheath body 232, as illustrated in Fig. 9, however, is much shorter, so that it can be entirely received within the epidural space of the patient, i.e., the sheath body 232 will not extend out of the patient's back when fully deployed within the epidural space. The electrical conductors 242, because they are exposed, are preferably composed of an electrically insulative material.
The kit 200 further comprises a pusher 214 that can be used to facilitate introduction of the respective secondary stimulation lead 204 along the primary stimulation lead 102 once the entire sheath body 232 of the secondary stimulation lead 204 is within the patient's back. The pusher 214 comprises a cylindrical rod 216 having a distal tip 218 and a proximal end 220, and a handle 222 mounted on the proximal end 220 of the rod 216. The distal tip 218 of the rod 216 is adapted to be received within an opening 224 (shown in Fig. 11 ) at the proximal end of the sheath body 232, thereby facilitating stable engagement between the pusher 214 and respective secondary stimulation lead 204.
The kit 200 can be installed and used in the same manner as the previously described kit 100 in treating chronic pain. In particular, the patient is prepared and the primary stimulation lead 102 is delivered into the epidural space 16 of the patient's spine, so that the electrodes 120 are placed adjacent the target stimulation "site 18 in the same manner described above with respect to Fig. 8A and 8B.
One of the secondary stimulation leads 204 is then delivered into the epidural space 16 in the same manner as the secondary stimulation lead 104 described above was delivered, with the exception that the pusher 214 is used to advance the secondary stimulation lead 204 along the primary stimulation lead 102 until fully deployed within the epidural space 16 (Fig. 12A). The remaining stimulation lead 204 is delivered into the epidural space 16 in the same manner to complete the stimulation lead assembly 210 (Fig. 12B).
Notably, because the percutaneous opening 24 need only support, at most, two sheath bodies at one time, it can be made smaller, or alternatively, additional stimulation leads with shortened sheath bodies can be introduced within the epidural space 16 without increasing the size of the percutaneous opening. After the stimulation lead assembly 210 has been formed within the epidural space, it is tested and optimized. The extension lead 108 is then connected between the stimulation leads 102/204 and the stimulation source 106, and the incisions are closed to fully implant the system, as previously described above.
Referring now to Fig. 16, an alternative embodiment of a secondary stimulation lead 304 engaged with one side of the primary stimulation 102 is illustrated. Although not shown, another secondary stimulation lead 304 can be engaged with the opposite side of the primary stimulation lead 102. The secondary stimulation lead 304 is similar to the previously described secondary stimulation lead 104, with the exception that the secondary stimulation lead 304 comprises a flap 303 on which the electrodes 140 are mounted. The secondary stimulation lead 304 can, alternatively, have a shortened sheath body much like the secondary stimulation lead 204 illustrated in Fig. 9. The flap 303 is designed to be constrained by the primary stimulation lead 102 to facilitate percutaneous delivery of the secondary stimulation lead 102, and released by the primary stimulation lead 102 to deploy the electrodes 140 into contact with the neural tissue.
In particular, the edge of the flap 303 comprises a coupling mechanism 305 that is designed to fit snugly within the respective slot 150 of the primary stimulation lead 102, along with the rail 152 of the secondary stimulation lead 102, when the secondary stimulation lead 304 is slidably engaged with the primary stimulation lead 102, as illustrated in Fig. 17. As the rail 152 of the secondary stimulation lead 102 exits the slot 150 of the primary stimulation lead 102, however, the coupling mechanism 305 of the flap 303 will release from the slot 150, thereby allowing the flap 303 to deploy, placing the electrodes 140 into contact with the underlying tissue, as illustrated in Fig. 18. It should be noted, that, when the secondary stimulation lead 304 is used in the kit 100 or kit 200, the slots 150 in the primary stimulation lead 102 will not terminate as hereinbefore described, but will rather open up at the distal tip of the primary stimulation lead 102, so that the flap 303 can exit the respective slot 150 and be released by the primary stimulation lead 102.
Installation and use of the secondary stimulation lead 304 in forming the stimulation lead assembly 110 illustrated in Fig. 2, or alternatively the stimulation lead assembly 210 illustrated in Fig. 10, is similar that previously described above.
Although in all of the previous embodiments, the primary stimulation lead 102 was used to provide a means of guiding the secondary stimulation leads 104 into the percutaneous opening within the patient and adjacent the target tissue region, as well as to provide a means of stimulating the tissue region, a guide member similar to the primary stimulation lead 102, but lacking stimulation capability, can be alternatively used to similarly guide the secondary stimulation leads 104 through the percutaneous opening to the target tissue region. In this case, only the secondary stimulation leads 104 will be used to stimulate tissue.
Claims (31)
1. A stimulation kit, comprising:
a first tissue stimulation lead comprising a first elongated body, a first stimulation element, and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body; and a second tissue stimulation lead comprising a second elongated body, a second stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
a first tissue stimulation lead comprising a first elongated body, a first stimulation element, and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body; and a second tissue stimulation lead comprising a second elongated body, a second stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
2. The stimulation kit of claim 1, wherein at least one of the first and second elongated bodies is cylindrically-shaped.
3. The stimulation kit of claims 1 or 2, wherein the greatest cross-sectional dimension of at least one of the first and second elongated bodies is 5 mm or less.
4. The stimulation kit of any of claims 1 - 3, wherein the first and second stimulation elements are electrodes.
5. The stimulation kit of any of claims 1 - 4, wherein the first and second stimulation elements are mounted on the respective first and second elongated bodies.
6. The stimulation kit of any of claims 1 - 5, wherein the first and second stimulation elements are configured to face a single direction when the first complementary coupling mechanism slidably engages the first coupling mechanism.
7. The stimulation kit of any of claims 1 - 6, wherein each of the first and second stimulation leads comprises a plurality of stimulation elements.
8. The stimulation kit of any of claims 1 - 7, wherein the first coupling mechanism and first complementary coupling mechanism are configured to slidably engage each other in a rail and slot arrangement.
9. The stimulation kit of any of claims 1 - 8, wherein the second complementary coupling mechanism extends along only a distal portion of the second elongated body.
10. The stimulation kit of any of claims 1 - 9, wherein the second elongated body is shorter than the first elongated body.
11. The stimulation kit of claim 1, wherein the second elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementary coupling mechanism from the coupling mechanism.
12. The stimulation kit of claim 11, wherein the second elongated body is pre-curved.
13. The stimulation kit of claim 11, wherein the second elongated body is configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body.
14. The stimulation kit of claim 13, further comprising a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry.
15. The stimulation kit of claim 13, wherein the second stimulation lead comprises a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
16. The stimulation kit of claim 1, wherein the second elongated body, and the second elongated body is configured to deploy from the first elongated body by bowing the portion of the second elongated body away from the first elongated body.
17. The stimulation kit of claim 1, wherein the second stimulation lead comprises a flap on which the respective stimulation element is disposed, the flap extending along a portion of the complementary coupling mechanism, and configured to be secured by the coupling mechanism when the portion of the complementary coupling mechanism slidably engages the coupling mechanism and released by the coupling mechanism when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism.
18. The stimulation kit of claim 1, wherein the first stimulation lead comprises another coupling mechanism longitudinally extending along at least a portion of the first elongated body, the stimulation kit further comprising a third stimulation lead comprising a third elongated body, a stimulation element mounted on the third elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism.
19. The stimulation kit of any of claims 1 - 18, further comprising a stimulation source configured to be coupled to the first and second stimulation leads.
20. A stimulation kit, comprising:
a primary tissue stimulation lead comprising a primary elongated body, a primary stimulation element mounted on the elongated body, first and second coupling mechanisms longitudinally extending along at least a portion of the elongated body, the first and second coupling mechanisms being substantially opposite each other; and two secondary tissue stimulation leads, each comprising a secondary elongated body, a secondary stimulation element mounted to the secondary elongated body, and a complementary coupling mechanism, wherein the complementary coupling mechanisms are configured to slidably engage the respective first and second coupling mechanisms.
a primary tissue stimulation lead comprising a primary elongated body, a primary stimulation element mounted on the elongated body, first and second coupling mechanisms longitudinally extending along at least a portion of the elongated body, the first and second coupling mechanisms being substantially opposite each other; and two secondary tissue stimulation leads, each comprising a secondary elongated body, a secondary stimulation element mounted to the secondary elongated body, and a complementary coupling mechanism, wherein the complementary coupling mechanisms are configured to slidably engage the respective first and second coupling mechanisms.
21. A stimulation kit, comprising:
a guide comprising a first elongated body and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body;
and a tissue stimulation lead comprising a second elongated body, a stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
a guide comprising a first elongated body and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body;
and a tissue stimulation lead comprising a second elongated body, a stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
22. The stimulation kit of claim 21, wherein the first elongated body is cylindrically-shaped.
23. The stimulation kit of either of claims 21 - 22, wherein the greatest cross-sectional dimension of the first elongated body is 5 mm or less.
24. The stimulation kit of any of claims 21 - 23, wherein the stimulation element is mounted on the elongated body.
25. The stimulation kit of any of claims 21 - 24, wherein the stimulation lead comprises a plurality of stimulation elements.
26. The stimulation kit of any of claims 21 - 25, wherein the first coupling mechanism and first complementary coupling mechanism are configured to slidably engage each other in a rail and slot arrangement.
27. The stimulation kit of claim 21, wherein the second elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementary coupling mechanism from the coupling mechanism:
28. The stimulation kit of claim 27, wherein the second elongated body is pre-curved.
29. The stimulation kit of claim 27, wherein the second elongated body is configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body.
30. The stimulation kit of claim 29, further comprising a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry.
31. The stimulation kit of claim 29, wherein the stimulation lead comprises a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/799,271 | 2004-03-12 | ||
US10/799,271 US7590454B2 (en) | 2004-03-12 | 2004-03-12 | Modular stimulation lead network |
PCT/US2005/007179 WO2005089861A1 (en) | 2004-03-12 | 2005-03-02 | Modular stimulation lead network |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2557743A1 true CA2557743A1 (en) | 2005-09-29 |
Family
ID=34920478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002557743A Abandoned CA2557743A1 (en) | 2004-03-12 | 2005-03-02 | Modular stimulation lead network |
Country Status (7)
Country | Link |
---|---|
US (2) | US7590454B2 (en) |
EP (1) | EP1722846B1 (en) |
JP (1) | JP4635045B2 (en) |
AT (1) | ATE510580T1 (en) |
CA (1) | CA2557743A1 (en) |
ES (1) | ES2363086T3 (en) |
WO (1) | WO2005089861A1 (en) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7072719B2 (en) * | 2001-09-20 | 2006-07-04 | Medtronic, Inc. | Implantable percutaneous stimulation lead with interlocking elements |
US20050203600A1 (en) * | 2004-03-12 | 2005-09-15 | Scimed Life Systems, Inc. | Collapsible/expandable tubular electrode leads |
US7590454B2 (en) | 2004-03-12 | 2009-09-15 | Boston Scientific Neuromodulation Corporation | Modular stimulation lead network |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
WO2006029257A2 (en) * | 2004-09-08 | 2006-03-16 | Spinal Modulation Inc. | Neurostimulation methods and systems |
US20120277839A1 (en) | 2004-09-08 | 2012-11-01 | Kramer Jeffery M | Selective stimulation to modulate the sympathetic nervous system |
EP1799129B1 (en) | 2004-10-15 | 2020-11-25 | Baxano, Inc. | Devices for tissue removal |
US8430881B2 (en) | 2004-10-15 | 2013-04-30 | Baxano, Inc. | Mechanical tissue modification devices and methods |
US8221397B2 (en) | 2004-10-15 | 2012-07-17 | Baxano, Inc. | Devices and methods for tissue modification |
US7553307B2 (en) * | 2004-10-15 | 2009-06-30 | Baxano, Inc. | Devices and methods for tissue modification |
US8617163B2 (en) | 2004-10-15 | 2013-12-31 | Baxano Surgical, Inc. | Methods, systems and devices for carpal tunnel release |
US20100331883A1 (en) | 2004-10-15 | 2010-12-30 | Schmitz Gregory P | Access and tissue modification systems and methods |
US7738969B2 (en) | 2004-10-15 | 2010-06-15 | Baxano, Inc. | Devices and methods for selective surgical removal of tissue |
US8257356B2 (en) | 2004-10-15 | 2012-09-04 | Baxano, Inc. | Guidewire exchange systems to treat spinal stenosis |
US7938830B2 (en) | 2004-10-15 | 2011-05-10 | Baxano, Inc. | Powered tissue modification devices and methods |
US20080103504A1 (en) * | 2006-10-30 | 2008-05-01 | Schmitz Gregory P | Percutaneous spinal stenosis treatment |
US7887538B2 (en) | 2005-10-15 | 2011-02-15 | Baxano, Inc. | Methods and apparatus for tissue modification |
US9101386B2 (en) | 2004-10-15 | 2015-08-11 | Amendia, Inc. | Devices and methods for treating tissue |
US8062300B2 (en) | 2006-05-04 | 2011-11-22 | Baxano, Inc. | Tissue removal with at least partially flexible devices |
US8048080B2 (en) | 2004-10-15 | 2011-11-01 | Baxano, Inc. | Flexible tissue rasp |
US9247952B2 (en) | 2004-10-15 | 2016-02-02 | Amendia, Inc. | Devices and methods for tissue access |
US20110190772A1 (en) | 2004-10-15 | 2011-08-04 | Vahid Saadat | Powered tissue modification devices and methods |
US7578819B2 (en) | 2005-05-16 | 2009-08-25 | Baxano, Inc. | Spinal access and neural localization |
US9050455B2 (en) | 2004-10-21 | 2015-06-09 | Medtronic, Inc. | Transverse tripole neurostimulation methods, kits and systems |
US7657316B2 (en) * | 2005-02-25 | 2010-02-02 | Boston Scientific Neuromodulation Corporation | Methods and systems for stimulating a motor cortex of the brain to treat a medical condition |
US7267690B2 (en) | 2005-03-09 | 2007-09-11 | Vertebral Technologies, Inc. | Interlocked modular disc nucleus prosthesis |
US8092456B2 (en) | 2005-10-15 | 2012-01-10 | Baxano, Inc. | Multiple pathways for spinal nerve root decompression from a single access point |
US8366712B2 (en) | 2005-10-15 | 2013-02-05 | Baxano, Inc. | Multiple pathways for spinal nerve root decompression from a single access point |
US8062298B2 (en) | 2005-10-15 | 2011-11-22 | Baxano, Inc. | Flexible tissue removal devices and methods |
US20080086034A1 (en) | 2006-08-29 | 2008-04-10 | Baxano, Inc. | Tissue Access Guidewire System and Method |
US7979131B2 (en) | 2006-01-26 | 2011-07-12 | Advanced Neuromodulation Systems, Inc. | Method of neurostimulation of distinct neural structures using single paddle lead to treat multiple pain locations and multi-column, multi-row paddle lead for such neurostimulation |
US8612009B2 (en) | 2006-01-26 | 2013-12-17 | Advanced Neuromodulation Systems, Inc. | Method of neurostimulation of distinct neural structures using single paddle lead to treat multiple pain locations and multi-column, multi-row paddle lead for such neurostimulation |
US7467016B2 (en) * | 2006-01-27 | 2008-12-16 | Cyberonics, Inc. | Multipolar stimulation electrode with mating structures for gripping targeted tissue |
AU2007212587B2 (en) | 2006-02-03 | 2012-07-12 | Synecor, Llc | Intravascular device for neuromodulation |
US20080046058A1 (en) * | 2006-04-28 | 2008-02-21 | Cross Thomas E | Methods for customizing implantable medical lead assemblies with improved flexibility and extensibility |
US20070282410A1 (en) * | 2006-04-28 | 2007-12-06 | Cross Thomas E Jr | Implantable medical lead assemblies with improved flexibility and extensibility and having a substantially two-dimensional nature |
US9737414B2 (en) | 2006-11-21 | 2017-08-22 | Vertebral Technologies, Inc. | Methods and apparatus for minimally invasive modular interbody fusion devices |
WO2008070808A2 (en) * | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Expandable stimulation leads and methods of use |
US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
WO2008070806A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Hard tissue anchors and delivery devices |
JP5414531B2 (en) | 2006-12-06 | 2014-02-12 | スパイナル・モデュレーション・インコーポレイテッド | Delivery device and systems and methods for stimulating neural tissue at multiple spinal levels |
US7797054B2 (en) * | 2007-01-12 | 2010-09-14 | Medtronic, Inc. | Expandable systems for medical electrical stimulation |
US9044592B2 (en) * | 2007-01-29 | 2015-06-02 | Spinal Modulation, Inc. | Sutureless lead retention features |
FR2912921B1 (en) * | 2007-02-26 | 2010-10-08 | Commissariat Energie Atomique | NON-RECTILINE PROBE AND SYSTEM FOR DEEP ELECTRICAL NEUROSTIMULATION COMPRISING SUCH A PROBE |
US8224453B2 (en) * | 2007-03-15 | 2012-07-17 | Advanced Neuromodulation Systems, Inc. | Spinal cord stimulation to treat pain |
WO2008130408A1 (en) * | 2007-04-20 | 2008-10-30 | Medtronic, Inc. | Implantable medical electrical lead and connector assembly |
US7996090B2 (en) * | 2007-04-30 | 2011-08-09 | Medtronic, Inc. | Methods of making implantable medical leads with a non-linear shape |
US20080269857A1 (en) * | 2007-04-30 | 2008-10-30 | Cross Thomas E | Implantable medical leads and lead assemblies with flexibility, extensibility and branched structures |
US7725198B2 (en) * | 2007-04-30 | 2010-05-25 | Medtronic, Inc. | Implantable medical lead assemblies with delivery tether |
US20080269858A1 (en) * | 2007-04-30 | 2008-10-30 | Cross Thomas E | Implantable medical leads with flexibility and extensibility, and having a substantially two-dimensional nature |
EP2194861A1 (en) | 2007-09-06 | 2010-06-16 | Baxano, Inc. | Method, system and apparatus for neural localization |
US9089707B2 (en) | 2008-07-02 | 2015-07-28 | The Board Of Regents, The University Of Texas System | Systems, methods and devices for paired plasticity |
US8457757B2 (en) | 2007-11-26 | 2013-06-04 | Micro Transponder, Inc. | Implantable transponder systems and methods |
US7751904B2 (en) * | 2007-11-29 | 2010-07-06 | Biotronik Crm Patent Ag | Electrode lead for implantation into a small heart vessel |
US8192436B2 (en) | 2007-12-07 | 2012-06-05 | Baxano, Inc. | Tissue modification devices |
EP2249918A1 (en) * | 2008-02-15 | 2010-11-17 | Cardiac Pacemakers, Inc. | Modular, zone-specific medical electrical lead design |
JP5048849B2 (en) * | 2008-02-15 | 2012-10-17 | カーディアック ペースメイカーズ, インコーポレイテッド | Medical electrical lead with proximal protection |
US7925352B2 (en) | 2008-03-27 | 2011-04-12 | Synecor Llc | System and method for transvascularly stimulating contents of the carotid sheath |
US8326439B2 (en) | 2008-04-16 | 2012-12-04 | Nevro Corporation | Treatment devices with delivery-activated inflatable members, and associated systems and methods for treating the spinal cord and other tissues |
US8880176B2 (en) * | 2008-05-19 | 2014-11-04 | Nevro Corporation | Implantable neural stimulation electrode assemblies and methods for stimulating spinal neural sites |
US8398641B2 (en) | 2008-07-01 | 2013-03-19 | Baxano, Inc. | Tissue modification devices and methods |
US8409206B2 (en) | 2008-07-01 | 2013-04-02 | Baxano, Inc. | Tissue modification devices and methods |
US9314253B2 (en) | 2008-07-01 | 2016-04-19 | Amendia, Inc. | Tissue modification devices and methods |
MX348805B (en) | 2008-07-14 | 2017-06-28 | Baxano Inc | Tissue modification devices. |
US9364338B2 (en) | 2008-07-23 | 2016-06-14 | Resspond Spinal Systems | Modular nucleus pulposus prosthesis |
KR101614561B1 (en) | 2008-07-23 | 2016-04-21 | 마르크 아이. 말베르크 | Modular nucleus pulposus prosthesis |
US9717910B2 (en) | 2008-09-04 | 2017-08-01 | Boston Scientific Neuromodulation Corporation | Multiple tunable central cathodes on a paddle for increased medial-lateral and rostral-caudal flexibility via current steering |
ES2462759T3 (en) | 2008-10-01 | 2014-05-26 | Sherwin Hua | System for pedicle screw stabilization guided by column vertebrae wire |
US9056197B2 (en) | 2008-10-27 | 2015-06-16 | Spinal Modulation, Inc. | Selective stimulation systems and signal parameters for medical conditions |
US9403020B2 (en) | 2008-11-04 | 2016-08-02 | Nevro Corporation | Modeling positions of implanted devices in a patient |
US20100137960A1 (en) * | 2008-12-03 | 2010-06-03 | Boston Scientific Neuromodulation Corporation | Implantable neurostimulators having reduced pocket stimulation |
EP2405823A4 (en) | 2009-03-13 | 2012-07-04 | Baxano Inc | Flexible neural localization devices and methods |
WO2010111358A2 (en) * | 2009-03-24 | 2010-09-30 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to parasthesia |
CA2761778A1 (en) * | 2009-05-15 | 2010-11-18 | Spinal Modulation, Inc. | Methods, systems and devices for neuromodulating spinal anatomy |
US8394102B2 (en) | 2009-06-25 | 2013-03-12 | Baxano, Inc. | Surgical tools for treatment of spinal stenosis |
US20110009933A1 (en) * | 2009-07-09 | 2011-01-13 | Boston Scientific Neuromodulation Corporation | Piggy-back percutaneous lead insertion kit |
EP2459274B1 (en) * | 2009-07-30 | 2015-11-11 | Richard North | Modular electrode and insertion tool |
EP2462981A4 (en) * | 2009-08-06 | 2013-01-23 | Terumo Corp | Electric stimulator |
JP2011036284A (en) * | 2009-08-06 | 2011-02-24 | Terumo Corp | Electric stimulator |
US8670837B2 (en) * | 2010-03-24 | 2014-03-11 | Khosrow Daneshvar | Method and means to adjust the positioning of stimulating neural and muscular electrode |
US11045221B2 (en) * | 2009-10-30 | 2021-06-29 | Medtronic, Inc. | Steerable percutaneous paddle stimulation lead |
EP2539016B1 (en) | 2010-02-22 | 2017-11-01 | Richard B. North | Percutaneous electrode system |
EP2568904B1 (en) | 2010-05-10 | 2019-10-02 | Spinal Modulation Inc. | Device for reducing migration |
US8965482B2 (en) | 2010-09-30 | 2015-02-24 | Nevro Corporation | Systems and methods for positioning implanted devices in a patient |
US8805519B2 (en) | 2010-09-30 | 2014-08-12 | Nevro Corporation | Systems and methods for detecting intrathecal penetration |
CA2823592C (en) | 2011-01-03 | 2021-11-23 | The Regents Of The University Of California | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
AU2012207115B2 (en) | 2011-01-21 | 2016-03-10 | California Institute Of Technology | A parylene-based microelectrode array implant for spinal cord stimulation |
CA2825763A1 (en) | 2011-02-02 | 2012-08-09 | Spinal Modulation, Inc. | Devices, systems and methods for the targeted treatment of movement disorders |
MX344095B (en) | 2011-03-24 | 2016-12-05 | Univ Louisville Res Found Inc | Neurostimulator. |
AU2012318335B2 (en) * | 2011-10-07 | 2017-06-15 | Anthony J. Colantonio | Lead coupler for multiple neurological stimulation leads |
US10092750B2 (en) | 2011-11-11 | 2018-10-09 | Neuroenabling Technologies, Inc. | Transcutaneous neuromodulation system and methods of using same |
AU2012334926B2 (en) | 2011-11-11 | 2017-07-13 | The Regents Of The University Of California | Transcutaneous spinal cord stimulation: noninvasive tool for activation of locomotor circuitry |
CN104220128B (en) | 2011-11-11 | 2016-12-07 | 神经赋能科技公司 | Enable the non-intruding neuroregulation device that motor function, sensory function, autonomic nervous function, sexual function, vasomotoricity and cognitive function recover |
AU2013211937B2 (en) | 2012-01-25 | 2016-07-28 | Nevro Corporation | Lead anchors and associated systems and methods |
EP2806943B1 (en) * | 2012-01-26 | 2020-11-04 | Boston Scientific Neuromodulation Corporation | Systems for identifying the circumferential positioning of electrodes of leads for electrical stimulation systems |
US9510953B2 (en) | 2012-03-16 | 2016-12-06 | Vertebral Technologies, Inc. | Modular segmented disc nucleus implant |
US9308022B2 (en) | 2012-12-10 | 2016-04-12 | Nevro Corporation | Lead insertion devices and associated systems and methods |
US9457195B2 (en) | 2013-01-10 | 2016-10-04 | Konstantin V. Slavin | Implantable medical device |
EP2968940B1 (en) | 2013-03-15 | 2021-04-07 | The Regents Of The University Of California | Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion |
US9731122B2 (en) | 2013-04-29 | 2017-08-15 | Rainbow Medical Ltd. | Electroosmotic tissue treatment |
US9919146B2 (en) | 2013-05-01 | 2018-03-20 | Sherwin Hua | Methods and systems for intraventricular brain stimulation |
US9265935B2 (en) | 2013-06-28 | 2016-02-23 | Nevro Corporation | Neurological stimulation lead anchors and associated systems and methods |
CA2925754C (en) | 2013-09-27 | 2023-02-21 | The Regents Of The University Of California | Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects |
WO2015106286A1 (en) | 2014-01-13 | 2015-07-16 | California Institute Of Technology | Neuromodulation systems and methods of using same |
US10265530B1 (en) | 2014-05-29 | 2019-04-23 | Stimwave Technologies Incorporated | Simulation with electrode arrays |
EP3183028A4 (en) | 2014-08-21 | 2018-05-02 | The Regents of the University of California | Regulation of autonomic control of bladder voiding after a complete spinal cord injury |
WO2016033369A1 (en) | 2014-08-27 | 2016-03-03 | The Regents Of The University Of California | Multi-electrode array for spinal cord epidural stimulation |
US10271899B2 (en) * | 2015-03-18 | 2019-04-30 | Medtronic Cryocath Lp | Multi-function device with treatment and sensing capabilities |
US9616221B2 (en) | 2015-07-08 | 2017-04-11 | Rainbow Medical Ltd. | Electrical treatment of Alzheimer's disease |
WO2017035512A1 (en) | 2015-08-26 | 2017-03-02 | The Regents Of The University Of California | Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject |
US10155107B2 (en) * | 2015-10-07 | 2018-12-18 | Medtronic, Inc. | Implantable modular electrode array assembly |
US10898716B2 (en) | 2015-10-29 | 2021-01-26 | Rainbow Medical Ltd. | Electrical substance clearance from the brain |
US11097122B2 (en) | 2015-11-04 | 2021-08-24 | The Regents Of The University Of California | Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel |
US11484706B2 (en) | 2015-12-29 | 2022-11-01 | Discure Technologies Ltd | Disc therapy |
US9770591B2 (en) | 2015-12-29 | 2017-09-26 | Rainbow Medical Ltd. | Disc therapy |
US10569086B2 (en) | 2017-01-11 | 2020-02-25 | Rainbow Medical Ltd. | Electrical microglial cell activation |
AU2018231031B2 (en) | 2017-03-09 | 2023-11-02 | Nevro Corp. | Paddle leads and delivery tools, and associated systems and methods |
US10758722B2 (en) | 2017-05-03 | 2020-09-01 | Rainbow Medical Ltd. | Electrical treatment of Parkinson's disease |
EP3421081B1 (en) | 2017-06-30 | 2020-04-15 | GTX medical B.V. | A system for neuromodulation |
US11033327B2 (en) * | 2017-10-30 | 2021-06-15 | St. Jude Medical, Cardiology Division, Inc. | Electrophysiology catheter with modular electrode structure |
JP2021507755A (en) | 2017-12-21 | 2021-02-25 | ガルバニ バイオエレクトロニクス リミテッド | Systems and methods configured to insert implants into the abdominal wall cavity |
EP3765141A1 (en) | 2018-03-14 | 2021-01-20 | Rainbow Medical Ltd. | Electrical substance clearance from the brain |
AU2019242906A1 (en) | 2018-03-29 | 2020-10-15 | Nevro Corp. | Leads having sidewall openings, and associated systems and methods |
ES2911465T3 (en) | 2018-11-13 | 2022-05-19 | Onward Medical N V | Control system for the reconstruction and/or restoration of a patient's movement |
DE18205817T1 (en) | 2018-11-13 | 2020-12-24 | Gtx Medical B.V. | SENSOR IN CLOTHING OF LIMBS OR FOOTWEAR |
EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
US11648399B2 (en) * | 2019-06-10 | 2023-05-16 | Boston Scientific Neuromodulation Corporation | Sensing reference electrode for percutaneous neuromodulation trials |
US10881858B1 (en) | 2019-09-18 | 2021-01-05 | Rainbow Medical Ltd. | Electrical substance clearance from the brain |
DE19211698T1 (en) | 2019-11-27 | 2021-09-02 | Onward Medical B.V. | Neuromodulation system |
US11298530B1 (en) | 2021-05-03 | 2022-04-12 | Discure Technologies Ltd. | Synergistic therapies for intervertebral disc degeneration |
US11344721B1 (en) | 2021-08-16 | 2022-05-31 | Rainbow Medical Ltd. | Cartilage treatment |
US11413455B1 (en) | 2022-02-08 | 2022-08-16 | Rainbow Medical Ltd. | Electrical treatment of Alzheimer's disease |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US538514A (en) | 1895-04-30 | haeselee | ||
US661047A (en) | 1900-08-29 | 1900-11-06 | Elbert G Graves | Cultivator and planter. |
US4141365A (en) | 1977-02-24 | 1979-02-27 | The Johns Hopkins University | Epidural lead electrode and insertion needle |
US4285347A (en) | 1979-07-25 | 1981-08-25 | Cordis Corporation | Stabilized directional neural electrode lead |
US4519403A (en) | 1983-04-29 | 1985-05-28 | Medtronic, Inc. | Balloon lead and inflator |
US4608985A (en) | 1984-10-11 | 1986-09-02 | Case Western Reserve University | Antidromic pulse generating wave form for collision blocking |
US4658835A (en) | 1985-07-25 | 1987-04-21 | Cordis Corporation | Neural stimulating lead with fixation canopy formation |
US4739768B2 (en) | 1986-06-02 | 1995-10-24 | Target Therapeutics Inc | Catheter for guide-wire tracking |
US5365926A (en) | 1986-11-14 | 1994-11-22 | Desai Jawahar M | Catheter for mapping and ablation and method therefor |
US4813934A (en) | 1987-08-07 | 1989-03-21 | Target Therapeutics | Valved catheter device and method |
US4869255A (en) | 1987-12-04 | 1989-09-26 | Ad-Tech Medical Instrument Corp. | Electrical connection device |
SE8800019D0 (en) | 1988-01-07 | 1988-01-07 | Knut Olof Edhag | FOR CARDIALLY DEFIBLATION USED INTRAVASCULES ELECTRO CABLE |
US4884579A (en) | 1988-04-18 | 1989-12-05 | Target Therapeutics | Catheter guide wire |
US5010895A (en) | 1989-08-03 | 1991-04-30 | Empi, Inc. | Expandable vaginal electrode |
US5005587A (en) | 1989-11-13 | 1991-04-09 | Pacing Systems, Inc. | Braid Electrode leads and catheters and methods for using the same |
US5342410A (en) | 1990-10-05 | 1994-08-30 | Eric Braverman | Apparatus and method for increasing the amplitude of P300 waves in the human brain |
US5170802A (en) | 1991-01-07 | 1992-12-15 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5224491A (en) | 1991-01-07 | 1993-07-06 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5107856A (en) * | 1991-01-10 | 1992-04-28 | Siemens-Pacesetter, Inc. | Multiple lead suture sleeve |
US5234437A (en) | 1991-12-12 | 1993-08-10 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusion coil assembly with threaded coupling |
EP0791333B1 (en) | 1991-12-12 | 1999-12-01 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusive coil assembly with interlocking coupling |
US5261916A (en) | 1991-12-12 | 1993-11-16 | Target Therapeutics | Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling |
US5358514A (en) | 1991-12-18 | 1994-10-25 | Alfred E. Mann Foundation For Scientific Research | Implantable microdevice with self-attaching electrodes |
US5509411A (en) | 1993-01-29 | 1996-04-23 | Cardima, Inc. | Intravascular sensing device |
SE9200803D0 (en) | 1992-03-16 | 1992-03-16 | Siemens Elema Ab | defibrillation |
US5239999A (en) | 1992-03-27 | 1993-08-31 | Cardiac Pathways Corporation | Helical endocardial catheter probe |
US5423877A (en) | 1992-05-04 | 1995-06-13 | David C. Mackey | Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion |
US5782239A (en) | 1992-06-30 | 1998-07-21 | Cordis Webster, Inc. | Unique electrode configurations for cardiovascular electrode catheter with built-in deflection method and central puller wire |
EP0580928A1 (en) | 1992-07-31 | 1994-02-02 | ARIES S.r.l. | A spinal electrode catheter |
US5306294A (en) | 1992-08-05 | 1994-04-26 | Ultrasonic Sensing And Monitoring Systems, Inc. | Stent construction of rolled configuration |
US5350397A (en) | 1992-11-13 | 1994-09-27 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
US5312415A (en) | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
US5250071A (en) | 1992-09-22 | 1993-10-05 | Target Therapeutics, Inc. | Detachable embolic coil assembly using interlocking clasps and method of use |
ATE176404T1 (en) | 1992-09-30 | 1999-02-15 | Cardiac Pacemakers Inc | HINGED CUSHION ELECTRODE FOR CARDIAC REACH WITH A LADDER-FREE AREA THAT SERVES AS A HINGE |
DE69315704T3 (en) | 1992-10-01 | 2002-08-01 | Cardiac Pacemakers Inc | STENT-LIKE STRUCTURE FOR DEFLICTION ELECTRODES |
US5263488A (en) | 1992-10-05 | 1993-11-23 | Nicolet Instrument Corporation | Method and apparatus for localization of intracerebral sources of electrical activity |
US5306272A (en) | 1992-11-02 | 1994-04-26 | Neuro Navigational Corporation | Advancer for surgical instrument |
SE9203734D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | defibrillation |
US5792187A (en) | 1993-02-22 | 1998-08-11 | Angeion Corporation | Neuro-stimulation to control pain during cardioversion defibrillation |
CA2158453C (en) | 1993-03-16 | 1999-11-16 | Thomas F. Kordis | Multiple electrode support structures |
US6572529B2 (en) | 1993-06-17 | 2003-06-03 | Wilk Patent Development Corporation | Intrapericardial assist method |
US5385528A (en) | 1993-06-17 | 1995-01-31 | Wilk; Peter J. | Intrapericardial assist device and associated method |
US5860974A (en) | 1993-07-01 | 1999-01-19 | Boston Scientific Corporation | Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft |
US5984909A (en) | 1993-08-13 | 1999-11-16 | Daig Corporation | Coronary sinus catheter |
US5417719A (en) | 1993-08-25 | 1995-05-23 | Medtronic, Inc. | Method of using a spinal cord stimulation lead |
US5464446A (en) | 1993-10-12 | 1995-11-07 | Medtronic, Inc. | Brain lead anchoring system |
US5582609A (en) | 1993-10-14 | 1996-12-10 | Ep Technologies, Inc. | Systems and methods for forming large lesions in body tissue using curvilinear electrode elements |
US5989280A (en) * | 1993-10-22 | 1999-11-23 | Scimed Lifesystems, Inc | Stent delivery apparatus and method |
EP1364677A3 (en) | 1993-11-10 | 2006-12-27 | Medtronic, Inc. | Electrode array catheter |
US5501703A (en) | 1994-01-24 | 1996-03-26 | Medtronic, Inc. | Multichannel apparatus for epidural spinal cord stimulator |
US5462545A (en) | 1994-01-31 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Catheter electrodes |
US5443492A (en) | 1994-02-02 | 1995-08-22 | Medtronic, Inc. | Medical electrical lead and introducer system for implantable pulse generator |
US5517989A (en) | 1994-04-01 | 1996-05-21 | Cardiometrics, Inc. | Guidewire assembly |
ATE310839T1 (en) | 1994-04-29 | 2005-12-15 | Scimed Life Systems Inc | STENT WITH COLLAGEN |
US5543864A (en) | 1994-10-11 | 1996-08-06 | Hudson Optical Corporation | Method and kit for attaching side shields to eyeglass temples |
US5603731A (en) | 1994-11-21 | 1997-02-18 | Whitney; Douglass G. | Method and apparatus for thwarting thrombosis |
US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
IL116561A0 (en) * | 1994-12-30 | 1996-03-31 | Target Therapeutics Inc | Severable joint for detachable devices placed within the body |
US5707354A (en) | 1995-04-17 | 1998-01-13 | Cardiovascular Imaging Systems, Inc. | Compliant catheter lumen and methods |
US5611345A (en) | 1995-04-24 | 1997-03-18 | Hibbeln; John F. | Medical instrument with improved ultrasonic visibility |
US5534007A (en) | 1995-05-18 | 1996-07-09 | Scimed Life Systems, Inc. | Stent deployment catheter with collapsible sheath |
US5702438A (en) | 1995-06-08 | 1997-12-30 | Avitall; Boaz | Expandable recording and ablation catheter system |
US6480743B1 (en) * | 2000-04-05 | 2002-11-12 | Neuropace, Inc. | System and method for adaptive brain stimulation |
US5755750A (en) | 1995-11-13 | 1998-05-26 | University Of Florida | Method and apparatus for selectively inhibiting activity in nerve fibers |
NL1001890C2 (en) | 1995-12-13 | 1997-06-17 | Cordis Europ | Catheter with plate-shaped electrode array. |
US5846238A (en) | 1996-01-19 | 1998-12-08 | Ep Technologies, Inc. | Expandable-collapsible electrode structures with distal end steering or manipulation |
US5891136A (en) | 1996-01-19 | 1999-04-06 | Ep Technologies, Inc. | Expandable-collapsible mesh electrode structures |
US5871483A (en) | 1996-01-19 | 1999-02-16 | Ep Technologies, Inc. | Folding electrode structures |
US6463328B1 (en) * | 1996-02-02 | 2002-10-08 | Michael Sasha John | Adaptive brain stimulation method and system |
US6066163A (en) | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US6152899A (en) | 1996-03-05 | 2000-11-28 | Vnus Medical Technologies, Inc. | Expandable catheter having improved electrode design, and method for applying energy |
US5713922A (en) | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
US5925070A (en) | 1996-04-04 | 1999-07-20 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of electrically excitable tissue |
US5716377A (en) | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5683422A (en) | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US6006134A (en) | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US5782798A (en) | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5752979A (en) | 1996-11-01 | 1998-05-19 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
US5800474A (en) | 1996-11-01 | 1998-09-01 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
US6071279A (en) | 1996-12-19 | 2000-06-06 | Ep Technologies, Inc. | Branched structures for supporting multiple electrode elements |
ES2208963T3 (en) | 1997-01-03 | 2004-06-16 | Biosense, Inc. | PRESSURE SENSITIVE VASCULAR ENDOPROTESIS. |
EP0855196A1 (en) | 1997-01-28 | 1998-07-29 | Sulzer Osypka GmbH | Defibrillation electrode |
US5938596A (en) | 1997-03-17 | 1999-08-17 | Medtronic, Inc. | Medical electrical lead |
US6015387A (en) | 1997-03-20 | 2000-01-18 | Medivas, Llc | Implantation devices for monitoring and regulating blood flow |
US5954761A (en) | 1997-03-25 | 1999-09-21 | Intermedics Inc. | Implantable endocardial lead assembly having a stent |
US5948007A (en) | 1997-04-30 | 1999-09-07 | Medtronic, Inc. | Dual channel implantation neurostimulation techniques |
US6128537A (en) | 1997-05-01 | 2000-10-03 | Medtronic, Inc | Techniques for treating anxiety by brain stimulation and drug infusion |
US6119044A (en) | 1997-06-02 | 2000-09-12 | Advanced Bionics Corporation | Cochlear electrode array with positioning stylet |
US6547788B1 (en) * | 1997-07-08 | 2003-04-15 | Atrionx, Inc. | Medical device with sensor cooperating with expandable member |
US5902236A (en) | 1997-09-03 | 1999-05-11 | Pmt Corporation | Tissue electrode for recording and stimulation |
US6231516B1 (en) | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US5967986A (en) | 1997-11-25 | 1999-10-19 | Vascusense, Inc. | Endoluminal implant with fluid flow sensing capability |
US6074407A (en) | 1997-10-14 | 2000-06-13 | Target Therapeutics, Inc. | Delivery catheter for occlusive implants |
US6016449A (en) | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6647296B2 (en) * | 1997-10-27 | 2003-11-11 | Neuropace, Inc. | Implantable apparatus for treating neurological disorders |
US6014589A (en) | 1997-11-12 | 2000-01-11 | Vnus Medical Technologies, Inc. | Catheter having expandable electrodes and adjustable stent |
US5931862A (en) | 1997-12-22 | 1999-08-03 | Pacesetter, Inc. | Medical lead and method of making and using with sodium sulfosuccinic ester |
US20020188207A1 (en) | 1998-01-08 | 2002-12-12 | Jacob Richter | Anchor for sensor implanted in a bodily lumen |
US6074507A (en) | 1998-01-09 | 2000-06-13 | Corrugating Roll Corporation | Corrugating roll with improved flute profile |
US6415187B1 (en) * | 1998-02-10 | 2002-07-02 | Advanced Bionics Corporation | Implantable, expandable, multicontact electrodes and insertion needle for use therewith |
US6205361B1 (en) | 1998-02-10 | 2001-03-20 | Advanced Bionics Corporation | Implantable expandable multicontact electrodes |
US6522932B1 (en) * | 1998-02-10 | 2003-02-18 | Advanced Bionics Corporation | Implantable, expandable, multicontact electrodes and tools for use therewith |
US5902331A (en) * | 1998-03-10 | 1999-05-11 | Medtronic, Inc. | Arrangement for implanting an endocardial cardiac lead |
EP1075302A1 (en) | 1998-04-30 | 2001-02-14 | Medtronic, Inc. | Multiple electrode lead body for spinal cord stimulation |
US6161047A (en) | 1998-04-30 | 2000-12-12 | Medtronic Inc. | Apparatus and method for expanding a stimulation lead body in situ |
US6018682A (en) | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US6319241B1 (en) | 1998-04-30 | 2001-11-20 | Medtronic, Inc. | Techniques for positioning therapy delivery elements within a spinal cord or a brain |
US6421566B1 (en) * | 1998-04-30 | 2002-07-16 | Medtronic, Inc. | Selective dorsal column stimulation in SCS, using conditioning pulses |
US5938689A (en) | 1998-05-01 | 1999-08-17 | Neuropace, Inc. | Electrode configuration for a brain neuropacemaker |
US6006124A (en) | 1998-05-01 | 1999-12-21 | Neuropace, Inc. | Means and method for the placement of brain electrodes |
US6179858B1 (en) | 1998-05-12 | 2001-01-30 | Massachusetts Institute Of Technology | Stent expansion and apposition sensing |
US6091980A (en) | 1998-05-12 | 2000-07-18 | Massachusetts Institute Of Technology | Stent slip sensing system and method |
US6266568B1 (en) | 1998-06-02 | 2001-07-24 | Advanced Bionics Corporation | Inflatable cochlear electrode array and method of making same |
DE19826624A1 (en) * | 1998-06-18 | 1999-12-23 | Merck Patent Gmbh | Pigment preparation |
US6094596A (en) | 1998-06-19 | 2000-07-25 | Angeron Corporation | Transvenous defibrillation lead system for use in middle cardiac vein |
US6027456A (en) | 1998-07-10 | 2000-02-22 | Advanced Neuromodulation Systems, Inc. | Apparatus and method for positioning spinal cord stimulation leads |
US6002964A (en) * | 1998-07-15 | 1999-12-14 | Feler; Claudio A. | Epidural nerve root stimulation |
US6370427B1 (en) | 1998-07-23 | 2002-04-09 | Intermedics, Inc. | Method and apparatus for dual chamber bi-ventricular pacing and defibrillation |
US6036689A (en) | 1998-09-24 | 2000-03-14 | Tu; Lily Chen | Ablation device for treating atherosclerotic tissues |
US6319251B1 (en) | 1998-09-24 | 2001-11-20 | Hosheng Tu | Medical device and methods for treating intravascular restenosis |
US6391643B1 (en) * | 1998-10-28 | 2002-05-21 | Cygnus, Inc. | Kit and method for quality control testing of an iontophoretic sampling system |
US6253109B1 (en) * | 1998-11-05 | 2001-06-26 | Medtronic Inc. | System for optimized brain stimulation |
IT1305062B1 (en) | 1998-12-23 | 2001-04-10 | Leonardo Cammilli | SINGLE INTRODUCTION CATHETER FOR MULTISITE STIMULATION OF THE FOUR CARDIAC CHAMBERS FOR TREATMENT OF PATHOLOGIES SUCH AS |
US6393325B1 (en) * | 1999-01-07 | 2002-05-21 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6192279B1 (en) | 1999-02-23 | 2001-02-20 | Medtronic, Inc. | Non-invasively maneuverable lead system |
US6161029A (en) | 1999-03-08 | 2000-12-12 | Medtronic, Inc. | Apparatus and method for fixing electrodes in a blood vessel |
DE19912635A1 (en) * | 1999-03-20 | 2000-09-21 | Biotronik Mess & Therapieg | Dilatable cardiac electrode arrangement for implantation, particularly in the coronary sinus of the heart |
US6136021A (en) | 1999-03-23 | 2000-10-24 | Cardiac Pacemakers, Inc. | Expandable electrode for coronary venous leads |
US6170488B1 (en) | 1999-03-24 | 2001-01-09 | The B. F. Goodrich Company | Acoustic-based remotely interrogated diagnostic implant device and system |
US6361528B1 (en) | 1999-04-05 | 2002-03-26 | Acist Medical Systems, Inc. | Dynamically compliant catheter |
US6330477B1 (en) | 1999-04-12 | 2001-12-11 | Medtronic, Inc. | Ventricular synchronized atrial pacing mode of implantable cardioverter/defibrillator |
US6317615B1 (en) * | 1999-04-19 | 2001-11-13 | Cardiac Pacemakers, Inc. | Method and system for reducing arterial restenosis in the presence of an intravascular stent |
US6216045B1 (en) | 1999-04-26 | 2001-04-10 | Advanced Neuromodulation Systems, Inc. | Implantable lead and method of manufacture |
US20010025192A1 (en) | 1999-04-29 | 2001-09-27 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6249707B1 (en) | 1999-04-30 | 2001-06-19 | Medtronic, Inc. | Apparatus and method for percutaneous implant of a paddle style lead |
US6353762B1 (en) | 1999-04-30 | 2002-03-05 | Medtronic, Inc. | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US6192280B1 (en) | 1999-06-02 | 2001-02-20 | Medtronic, Inc. | Guidewire placed implantable lead with tip seal |
US6539263B1 (en) * | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
AU6953300A (en) | 1999-07-07 | 2001-01-22 | Cardiac Pacemakers, Inc. | Endocardial electrode assembly having conductive fixation features |
US6516227B1 (en) * | 1999-07-27 | 2003-02-04 | Advanced Bionics Corporation | Rechargeable spinal cord stimulator system |
EP1106202A3 (en) | 1999-11-30 | 2004-03-31 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Electrode for intravascular stimulation, cardioversion and /or defibrillation |
JP2003516206A (en) * | 1999-12-07 | 2003-05-13 | クラスノウ インスティテュート | Adaptive electric field regulation of the nervous system |
US6662055B1 (en) * | 1999-12-17 | 2003-12-09 | Impulse Dynamics Nv | Multi-electrode intravascular lead |
EP1246665B1 (en) * | 2000-01-07 | 2005-08-24 | Biowave Corporation | Electrotherapy apparatus |
US6587733B1 (en) * | 2000-02-08 | 2003-07-01 | Medtronic, Inc. | Percutaneous surgical lead body with directed stimulation |
US6418344B1 (en) | 2000-02-24 | 2002-07-09 | Electrocore Techniques, Llc | Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex |
US6430442B1 (en) * | 2000-02-29 | 2002-08-06 | Medtronic, Inc. | Split contact with super elastic retaining ring for implantable medical device |
US6466822B1 (en) * | 2000-04-05 | 2002-10-15 | Neuropace, Inc. | Multimodal neurostimulator and process of using it |
US6837886B2 (en) | 2000-05-03 | 2005-01-04 | C.R. Bard, Inc. | Apparatus and methods for mapping and ablation in electrophysiology procedures |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
FR2809017B1 (en) * | 2000-05-16 | 2002-08-09 | Ela Medical Sa | REQUIRED FOR PLACEMENT OF AN IMPLANTABLE HEART CAVITY PACING LEAD IN THE CORONARY NETWORK |
US6408214B1 (en) | 2000-07-11 | 2002-06-18 | Medtronic, Inc. | Deflectable tip catheter for CS pacing |
US6895283B2 (en) | 2000-08-10 | 2005-05-17 | Advanced Neuromodulation Systems, Inc. | Stimulation/sensing lead adapted for percutaneous insertion |
US6510347B2 (en) * | 2000-08-17 | 2003-01-21 | William N. Borkan | Spinal cord stimulation leads |
US6591138B1 (en) * | 2000-08-31 | 2003-07-08 | Neuropace, Inc. | Low frequency neurostimulator for the treatment of neurological disorders |
US6529774B1 (en) * | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US6369325B1 (en) * | 2000-11-20 | 2002-04-09 | Chung-Ching Wu | Switch box for a ceiling fan |
US6697676B2 (en) | 2000-12-21 | 2004-02-24 | Medtronic, Inc. | Medical electrical lead having an expandable electrode assembly |
US6445953B1 (en) * | 2001-01-16 | 2002-09-03 | Kenergy, Inc. | Wireless cardiac pacing system with vascular electrode-stents |
US6600954B2 (en) * | 2001-01-25 | 2003-07-29 | Biocontrol Medical Bcm Ltd. | Method and apparatus for selective control of nerve fibers |
US6597953B2 (en) * | 2001-02-20 | 2003-07-22 | Neuropace, Inc. | Furcated sensing and stimulation lead |
US6671544B2 (en) * | 2001-06-28 | 2003-12-30 | Medtronic, Inc. | Low impedance implantable extension for a neurological electrical stimulator |
US6606521B2 (en) * | 2001-07-09 | 2003-08-12 | Neuropace, Inc. | Implantable medical lead |
US7455666B2 (en) | 2001-07-13 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and apparatuses for navigating the subarachnoid space |
US6600956B2 (en) * | 2001-08-21 | 2003-07-29 | Cyberonics, Inc. | Circumneural electrode assembly |
US7072719B2 (en) * | 2001-09-20 | 2006-07-04 | Medtronic, Inc. | Implantable percutaneous stimulation lead with interlocking elements |
US6909918B2 (en) * | 2001-10-10 | 2005-06-21 | Medtronic, Inc. | Implantable percutaneous stimulation lead with lead carrier |
DE10153842A1 (en) * | 2001-10-24 | 2003-05-08 | Biotronik Mess & Therapieg | electrode assembly |
US6835311B2 (en) | 2002-01-31 | 2004-12-28 | Koslow Technologies Corporation | Microporous filter media, filtration systems containing same, and methods of making and using |
WO2003063692A2 (en) * | 2002-02-01 | 2003-08-07 | The Cleveland Clinic Foundation | Delivery device for stimulating the sympathetic nerve chain |
AU2003223583A1 (en) | 2002-04-11 | 2003-10-27 | Transvascular, Inc. | Devices and methods for transluminal or transthoracic interstitial electrode placement |
US20030199962A1 (en) | 2002-04-22 | 2003-10-23 | Chester Struble | Anti-slip leads for placement within tissue |
US7697995B2 (en) | 2002-04-25 | 2010-04-13 | Medtronic, Inc. | Surgical lead paddle |
US7283861B2 (en) | 2002-04-30 | 2007-10-16 | Alexander Bystritsky | Methods for modifying electrical currents in neuronal circuits |
US6988007B1 (en) * | 2002-08-13 | 2006-01-17 | Pacesetter, Inc. | Single pass telescoping cardiac lead for the left heart |
US7047084B2 (en) | 2002-11-20 | 2006-05-16 | Advanced Neuromodulation Systems, Inc. | Apparatus for directionally stimulating nerve tissue |
WO2004062470A2 (en) | 2003-01-03 | 2004-07-29 | Advanced Neuromodulation Systems, Inc. | System and method for stimulation of a person’s brain stem |
US7591845B2 (en) | 2003-02-19 | 2009-09-22 | Taewoong Medical Co., Ltd. | Stent for high frequency thermotherapy |
US6999820B2 (en) | 2003-05-29 | 2006-02-14 | Advanced Neuromodulation Systems, Inc. | Winged electrode body for spinal cord stimulation |
US20050004639A1 (en) * | 2003-07-03 | 2005-01-06 | Advanced Neuromodulation Systems, Inc. | Medical lead with resorbable material |
US20050137646A1 (en) | 2003-12-22 | 2005-06-23 | Scimed Life Systems, Inc. | Method of intravascularly delivering stimulation leads into brain |
US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US7590454B2 (en) | 2004-03-12 | 2009-09-15 | Boston Scientific Neuromodulation Corporation | Modular stimulation lead network |
US7177702B2 (en) | 2004-03-12 | 2007-02-13 | Scimed Life Systems, Inc. | Collapsible/expandable electrode leads |
US20050203600A1 (en) | 2004-03-12 | 2005-09-15 | Scimed Life Systems, Inc. | Collapsible/expandable tubular electrode leads |
US8412348B2 (en) | 2004-05-06 | 2013-04-02 | Boston Scientific Neuromodulation Corporation | Intravascular self-anchoring integrated tubular electrode body |
US7937160B2 (en) | 2004-12-10 | 2011-05-03 | Boston Scientific Neuromodulation Corporation | Methods for delivering cortical electrode leads into patient's head |
-
2004
- 2004-03-12 US US10/799,271 patent/US7590454B2/en not_active Expired - Fee Related
-
2005
- 2005-03-02 AT AT05724681T patent/ATE510580T1/en not_active IP Right Cessation
- 2005-03-02 EP EP05724681A patent/EP1722846B1/en not_active Not-in-force
- 2005-03-02 ES ES05724681T patent/ES2363086T3/en active Active
- 2005-03-02 CA CA002557743A patent/CA2557743A1/en not_active Abandoned
- 2005-03-02 WO PCT/US2005/007179 patent/WO2005089861A1/en not_active Application Discontinuation
- 2005-03-02 JP JP2007502876A patent/JP4635045B2/en not_active Expired - Fee Related
-
2009
- 2009-08-27 US US12/549,223 patent/US8185208B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8185208B2 (en) | 2012-05-22 |
US20050203599A1 (en) | 2005-09-15 |
EP1722846B1 (en) | 2011-05-25 |
WO2005089861A1 (en) | 2005-09-29 |
JP4635045B2 (en) | 2011-02-16 |
EP1722846A1 (en) | 2006-11-22 |
US20090319012A1 (en) | 2009-12-24 |
US7590454B2 (en) | 2009-09-15 |
ES2363086T3 (en) | 2011-07-20 |
ATE510580T1 (en) | 2011-06-15 |
JP2007528776A (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1722846B1 (en) | Modular stimulation lead network | |
US7177702B2 (en) | Collapsible/expandable electrode leads | |
US8019441B2 (en) | Collapsible/expandable tubular electrode leads | |
US8224459B1 (en) | Insertion tool for paddle-style electrode | |
US8983625B2 (en) | Systems and methods for electrically stimulating patient tissue on or around one or more bony structures | |
US7392093B2 (en) | Electrical stimulation system including a device for partially shielding electrical energy emitted from one or more electrical stimulation leads implanted in a human's body | |
US10369354B2 (en) | Systems and method for anchoring a lead for neurostimulation of a target anatomy | |
EP2318090B1 (en) | Implantable neural stimulation electrode assemblies | |
US20030078633A1 (en) | Methods and implantable apparatus for electrical therapy | |
US20050004639A1 (en) | Medical lead with resorbable material | |
WO2005082453A1 (en) | System and method for neurological stimulation of peripheral nerves to treat low back pain | |
US20140180305A1 (en) | Insertion tool for paddle-style electrode | |
US20150005783A1 (en) | Assembly kit for creating paddle-style lead from one or several percutaneous leads and method of lead implantation | |
US10376689B2 (en) | Leads for extraforaminal stimulation of dorsal roots and dorsal root ganglia and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20150303 |